NanoViricides (NNVC) 10-K/A 30 Sep 14 2014 FY Annual report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2014	Sep. 29, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'NANOVIRICIDES, INC.	'	'
Entity Central Index Key	'0001379006	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Trading Symbol	'NNVC	'	'
Entity Common Stock, Shares Outstanding	'	56,450,600	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$201,817,163

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
CURRENT ASSETS:	'	'
Cash and cash equivalents	$36,696,892	$13,923,245
Prepaid expenses	108,089	51,597
Other current assets	150,000	0
Total Current Assets	37,664,202	14,521,625
PROPERTY AND EQUIPMENT	'	'
Property and equipment	6,736,742	1,505,648
Accumulated depreciation	-1,239,986	-1,036,752
Property and Equipment, Net	5,496,756	468,896
TRADEMARK	'	'
Trademark	458,954	458,954
Accumulated amortization	-50,696	-41,921
Trademark, net	408,258	417,033
SECURITY DEPOSIT	1,000,000	1,000,000
Total Assets	44,569,216	16,407,554
CURRENT LIABILITIES:	'	'
Accounts payable	376,446	263,258
Accounts payable - related parties	758,676	710,567
Accrued expenses	91,838	204,359
Total Current Liabilities	1,226,960	1,178,184
LONG TERM LIABILITIES:	'	'
Derivative liability	5,699,703	3,751,645
Total Long Term Liabilities	14,737,271	7,219,718
Total Liabilities	15,964,231	8,397,902
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY:	'	'
Common stock, $0.001 par value; 85,714,286 shares authorized; 54,620,993, and 47,026,173 shares issued and outstanding, respectively	54,621	47,026
Additional paid-in capital	80,953,428	46,259,420
Accumulated Deficit	-52,406,258	-38,299,784
Total Stockholders' Equity	28,604,985	8,009,652
Total Liabilities and Stockholders' Equity	44,569,216	16,407,554
Series B Debentures [Member]	'	'
LONG TERM LIABILITIES:	'	'
Debentures payable	4,037,568	3,468,073
Series C Debentures [Member]	'	'
LONG TERM LIABILITIES:	'	'
Debentures payable	5,000,000	0
Related Party [Member]	'	'
CURRENT ASSETS:	'	'
Prepaid expenses	709,221	546,783
Series A Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	3,194	2,990
Series B Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY:	'	'
Preferred stock	$0	$0

Balance_Sheets_Parenthetical

Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	'	'	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	'	'	4,000,000	4,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued	'	'	3,193,079	2,990,000	0	0	0	0
Preferred stock, shares outstanding	'	'	3,193,079	2,990,000	0	0	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00	'	'	'	'	'	'
Common stock, shares authorized	85,714,286	85,714,286	'	'	'	'	'	'
Common stock, shares issued	54,620,993	47,026,173	'	'	'	'	'	'
Common stock, shares, outstanding	54,620,993	47,026,173	'	'	'	'	'	'

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
OPERATING EXPENSES	'	'	'
Research and development	$5,131,523	$4,292,909	$4,265,933
General and administrative	3,535,849	2,297,470	1,815,816
Total operating expenses	8,667,372	6,590,379	6,081,749
LOSS FROM OPERATIONS	-8,667,372	-6,590,379	-6,081,749
OTHER INCOME (EXPENSE):	'	'	'
Interest income	171,001	55,587	46,787
Interest Expense	-3,092,550	-962,535	'
Discount on convertible debentures	-569,495	-129,006	0
Change in fair market value of derivatives	-1,948,058	-1,249,335	-172,245
Other income (expense), net	-5,439,102	-2,285,289	-125,458
LOSS BEFORE INCOME TAXES	-14,106,474	-8,875,668	-6,207,207
INCOME TAX PROVISION	0	0	0
NET LOSS	($14,106,474)	($8,875,668)	($6,207,207)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED: (in dollars per share)	($0.28)	($0.19)	($0.15)
Weighted average common shares outstanding - basic and diluted (in shares)	51,225,818	45,892,549	42,763,481

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Subscription Received [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]
Balance at Jun. 30, 2011	$10,170,891	$41,012	$33,344,437	$0	($23,216,909)	$2,348	$3	'
Balance (in shares) at Jun. 30, 2011	'	41,013,828	'	'	'	2,347,857	2,857	'
Common shares issued for conversion of Series B Preferred Shares, July One	90	26	64	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July One (in shares)	'	25,710	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July One	-10	'	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July One (in shares)	'	0	'	'	'	'	-2,857	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, July Two (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued as dividend to Seaside 88, LP, July One	381	0	381	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One (in shares)	'	99	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July Two	378	108	270	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, July Two (in shares)	'	107,943	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, July One	-381	'	-381	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July One	17,881	'	17,881	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July Two	68,425	'	68,425	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, July	2,500,000	'	2,499,929	'	'	'	71	'
Series B Preferred Shares Issued During Period Issued For July	'	0	'	'	'	'	71,429	'
Warrants issued to Scientific Advisory Board, For August	56,400	'	56,400	'	'	'	'	'
Common shares issued for consulting and legal services, August	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	1,504	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One	8,055	2	8,053	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One (in shares)	'	2,345	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, August One	437	125	312	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, August One (in shares)	'	124,911	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, August One	69,193	'	69,193	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, August	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, August (in shares)	'	0	'	'	'	'	-11,428	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August One	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, August One (in shares)	'	0	'	'	'	'	-11,429	'
Dividend paid to Seaside 88, LP, August One	-8,055	'	-8,055	'	'	'	'	'
Common shares issued in conversion of Series B Preferred Shares, August Two	420	120	300	'	'	'	'	'
Common shares issued in conversion of Series B Preferred Shares, August Two (in shares)	'	119,951	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, August Two	-6,521	'	-6,521	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two	6,521	2	6,519	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two (in shares)	'	1,955	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, August Two	69,351	'	69,351	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	1,602	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One	-40	'	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for conversion of Series B Preferred Shares, September One	423	121	302	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September One (in shares)	'	120,821	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One	4,986	2	4,984	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One (in shares)	'	1,504	'	'	'	'	'	'
Series A Preferred Shares amendment of valuation arising from Amendment of certificate of Designation, June	0	0	0	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares ,September One	69,887	'	69,887	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two	3,452	0	3,452	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two (in shares)	'	1,055	'	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares	-430,283	0	-430,283	'	'	'	'	'
Dividend paid to Seaside 88, LP, September	-4,986	'	-4,986	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September Two	428	122	306	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, September Two (in shares)	'	122,186	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September Two	-40	'	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP,September Two (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - retirement of Series B Preferred Shares, For September Two	69,970	'	69,970	'	'	'	'	'
Dividend to Seaside 88, LP, paid September Two	-3,452	'	-3,452	'	'	'	'	'
Dividend paid to Seaside 88, LP, October One	-1,918	0	-1,918	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October One	-40	0	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for conversion of Series B Preferred Shares, October One	514	147	367	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, October One (in shares)	'	146,946	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For October One	69,496	0	69,496	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One	1,918	1	1,917	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One (in shares)	'	649	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October Two	-10	0	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, October Two (in shares)	'	0	'	'	'	'	-2,857	'
Common shares issued for conversion of Series B Preferred Shares, October Two	144	41	103	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, October Two (in shares)	'	41,281	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two (in shares)	'	146	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October Two	-384	0	-384	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, October Two	17,790	0	17,790	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	1,868	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November One	579	165	414	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November One (in shares)	'	165,313	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November One (in shares)	'	0	'	'	'	'	-11,429	'
Placement Agents Fees related to sale of Convertible Preferred shares, November	-160,000	0	-160,000	'	'	'	'	'
Series B Preferred Shares issued to SeaSide 88, LP, November	2,500,000	0	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, November (in shares)	'	0	'	'	'	'	71,429	'
Common shares issued as dividend to Seaside 88, LP, For November One	7,479	3	7,476	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November One (in shares)	'	2,946	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-7,479	0	-7,479	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, For November One	68,297	0	68,297	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares per share, November Two	579	165	414	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Two (in shares)	'	183,639	'	'	'	'	'	'
Derivative liability - Retirement of Series B Preferred Shares, For November Two	68,411	0	68,411	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Two	-40	0	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Two (in shares)	'	0	'	'	'	'	-11,428	'
Dividend paid to Seaside 88, LP, November Two	-6,521	0	-6,521	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two	6,521	3	6,518	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-7,479	0	-7,479	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Three	643	184	459	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November Three (in shares)	'	2,897	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Three	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, November Three (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - Retirement of Series B Preferred Shares, For November Three	68,591	0	68,591	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	56,400	0	56,400	'	'	'	'	'
Common shares issued for consulting and legal services For November	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	2,107	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December One	751	215	536	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December One (in shares)	'	214,661	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December (in shares)	'	0	'	'	'	'	-11,429	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, December One	-40	0	-28	'	'	'	-12	'
Common shares issued as Dividend to Seaside 88, LP, December	4,986	3	4,983	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December (in shares)	'	2,514	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, For December One	3,450	2	3,448	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, For December One (in shares)	'	1,948	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, December	-4,986	0	-4,986	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series C	-1,090,017	0	-1,090,017	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, December	68,753	0	68,753	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, December One	68,965	0	68,965	'	'	'	'	'
Dividend paid to Seaside 88, LP, December One	-3,452	0	-3,452	'	'	'	'	'
Common shares issued for consulting and legal services For December	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	2,687	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January One (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares January One	788	225	563	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January One (in shares)	'	225,158	'	'	'	'	'	'
Common shares issued for consulting and legal services For January	6,000	3	5,997	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One	1,918	1	1,917	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One (in shares)	'	1,069	'	'	'	'	'	'
Derivative liability - retirement of Series C Preferred Shares For January One	69,222	0	69,222	'	'	'	'	'
Dividend paid to Seaside 88, LP January One	-1,918	0	-1,918	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January Two	209	60	149	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares January Two (in shares)	'	59,585	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Two	-384	0	-384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two (in shares)	'	225	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For January Two	69,883	0	69,883	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January Two	-10	0	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP January Two (in shares)	'	0	'	'	'	'	-2,857	'
Placement Agents Fees related to sale of Convertible Preferred shares, February	-150,000	0	-150,000	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, March Two	4,986	2	4,984	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, March Two (in shares)	'	2,232	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April (in shares)	'	0	'	'	'	'	-11,429	'
Series B Preferred Shares issued to SeaSide 88, LP, February	2,500,000	0	2,499,929	'	'	'	71	'
Series B Preferred Shares issued to SeaSide 88, LP, February (in shares)	'	0	'	'	'	'	71,429	'
Common shares issued for consulting and legal services For January (in shares)	'	2,962	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	51,000	0	51,000	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, February	-6,250	0	-6,250	'	'	'	'	'
Common shares issued for consulting and legal services February	6,000	2	5,998	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	2,219	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February One	717	205	512	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February One (in shares)	'	204,898	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For February One	7,479	3	7,476	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For February One (in shares)	'	3,314	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February One (in shares)	'	0	'	'	'	'	-11,429	'
Dividend paid to Seaside 88, LP February One	-7,479	0	-7,479	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares For February One	68,169	0	68,169	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February Two	576	165	411	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares February Two (in shares)	'	164,589	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February Two	-40	0	-28	'	'	'	-12	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP February Two (in shares)	'	0	'	'	'	'	-11,428	'
Derivative liability - retirement of Series B Preferred Shares February Two	68,423	0	68,423	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares March One	628	180	448	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares March One (in shares)	'	179,511	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP March One	6,521	3	6,518	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP March One (in shares)	'	2,926	'	'	'	'	'	'
Dividend paid to Seaside 88, LP March One	-6,521	0	-6,521	'	'	'	'	'
Common shares issued for employee stock compensation, March	181,874	71	181,803	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	71,429	'	'	'	'	'	'
Derivative Liability - Retirement of Series B Preferred Shares March One	68,602	0	68,602	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March	634,408	0	634,239	'	'	169	'	'
Series A Preferred Shares issued for employee stock compensation, March (in shares)	'	0	'	'	'	169,643	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March One (in shares)	'	0	'	'	'	'	-11,429	'
Common shares issued for conversion of Series B Preferred Shares, March Two	636	182	454	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, March Two (in shares)	'	181,712	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March Two	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP March Two (in shares)	'	0	'	'	'	'	-11,429	'
Derivative liability - retirement of Series B Preferred Shares, March Two	68,862	0	68,862	'	'	'	'	'
Common shares issued for consulting and legal services, For March	6,000	2	5,998	'	'	'	'	'
Dividend paid to Seaside 88, LP March Two	-4,986	0	-4,986	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	2,208	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	2,728	'	'	'	'	'	'
Shares issued in conversion of Series B Preferred Shares to Common Stock, April (in shares)	'	188,999	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares April One	785	224	561	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, April One (in shares)	'	224,415	'	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April	3,452	2	3,450	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April (in shares)	'	1,631	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April One	-40	0	-29	'	'	'	-11	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, April One (in shares)	'	0	'	'	'	'	-11,429	'
Shares issued in conversion of Series B Preferred Shares to Common Stock, April	661	189	472	'	'	'	'	'
Dividend to Seaside 88, LP, April One	-1,918	0	-1,918	'	'	'	'	'
Dividend to Seaside 88, LP, April	-3,452	0	-3,452	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, April One	69,224	0	69,224	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series B, April	69,098	0	69,098	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April One	1,918	1	1,917	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, April One (in shares)	'	1,023	'	'	'	'	'	'
Derivative liability - issuance of Series B Preferred Shares, Two	-429,768	'	-429,768	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One	199	57	142	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, May One (in shares)	'	56,673	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	47,400	0	47,400	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One	384	0	384	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, May One (in shares)	'	215	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One	-10	0	-7	'	'	'	-3	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, May One (in shares)	'	0	'	'	'	'	-2,857	'
Common shares issued for consulting and legal services, May	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services, May (in shares)	'	2,561	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, May One	-384	0	-384	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, May One	69,892	0	69,892	'	'	'	'	'
Series C Preferred Shares issued to SeaSide 88, LP, June	2,500,000	0	2,499,999	'	'	'	'	1
Series C Preferred Shares issued to SeaSide 88, LP, June (in shares)	'	0	'	'	'	'	'	714
Legal Fees related to Sale of Convertible Preferred Stock, June	-25,000	0	-25,000	'	'	'	'	'
Common shares issued for consulting and legal services, June	5,999	2	5,997	'	'	'	'	'
Common shares issued for consulting and legal services, June (in shares)	'	2,814	'	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, June	298	85	213	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, June (in shares)	'	85,278	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, June	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, June (in shares)	'	0	'	'	'	'	'	-42
Series A Preferred Shares issued for employee stock compensation, June One	345,172	0	344,872	'	'	300	'	'
Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued For June One	'	0	'	'	'	300,000	'	'
Derivative Liability - Retirement of Preferred Series C, June	63,704	0	63,704	'	'	'	'	'
Shares of Series A Preferred issued for legal services	3,287	0	3,284	'	'	3	'	'
Shares of Series A Preferred issued for legal services (in shares)	'	0	'	'	'	2,857	'	'
Placement Agents Fees related to sale of Convertible Preferred shares, June	-150,000	0	-150,000	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP December One (in shares)	'	0	'	'	'	'	-11,428	'
Common shares issued for consulting and legal services July	6,000	1	5,999	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	1,361	'	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series B,November	-429,804	0	-429,804	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, November	-25,000	0	-25,000	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November	512	146	366	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, November (in shares)	'	146,225	'	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December Two	798	228	570	'	'	'	'	'
Common shares issued for conversion of Series B Preferred Shares, December Two (in shares)	'	227,653	'	'	'	'	'	'
Placement Agents fees related to sale of Convertible Preferred shares, July 26, 2011	-150,000	'	-150,000	'	'	'	'	'
Legal Fees related to Sale of Convertible Preferred Stock, July 26, 2011	-6,250	'	-6,250	'	'	'	'	'
Net loss	-6,207,207	0	0	'	-6,207,207	'	'	'
Balance at Jun. 30, 2012	13,850,193	44,460	43,227,028	0	-29,424,116	2,820	0	1
Balance (in shares) at Jun. 30, 2012	'	44,460,629	'	'	'	2,820,357	'	672
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July Two (in shares)	'	0	'	'	'	'	'	-37
Dividend paid to Seaside 88, LP, July Two	-8,629	0	-8,629	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, July One	212	61	151	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, July One (in shares)	'	60,685	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One	9,026	5	9,021	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July One (in shares)	'	5,256	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, July One	-9,026	0	-9,026	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, July One	44,190	0	44,190	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July One	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, July One (in shares)	'	0	'	'	'	'	'	-29
Shares issued in conversion of Series C Preferred Shares to Common Stock, July Two	271	78	193	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, July Two (in shares)	'	77,535	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, July Two	53,032	0	53,032	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July Two	8,629	5	8,624	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, July Two (in shares)	'	5,221	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For August	40,800	0	40,800	'	'	'	'	'
Common shares issued for consulting and legal services, August	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	2,956	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One	8,138	5	8,133	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August One (in shares)	'	5,391	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August One (in shares)	'	0	'	'	'	'	'	-34
Shares issued in conversion of Series C Preferred Shares to Common Stock, August One	281	80	201	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, August One (in shares)	'	80,270	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, August One	-8,138	0	-8,138	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, August One	51,555	0	51,555	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, August Two	575	164	411	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, August Two (in shares)	'	164,226	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, August Two (in shares)	'	0	'	'	'	'	'	-79
Dividend paid to Seaside 88, LP, August Two	-7,684	0	-7,684	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two	7,684	5	7,679	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, August Two (in shares)	'	4,573	'	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, August Two	121,054	0	121,054	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	2,765	'	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September One	763	218	545	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September One (in shares)	'	218,039	'	'	'	'	'	'
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One	-1	0	0	'	'	'	'	-1
Retirement of Series B Preferred Shares converted into common stock by SeaSide 88, LP, September One (in shares)	'	0	'	'	'	'	'	-126
Common shares issued as dividend to Seaside 88, LP, September One	6,625	3	6,622	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, September One (in shares)	'	3,279	'	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two	4,936	3	4,933	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, September Two (in shares)	'	2,735	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, September Two	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, September Two (in shares)	'	0	'	'	'	'	'	-81
Dividend paid to Seaside 88, LP, September	-6,625	0	-6,625	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares, For September One	236,481	0	236,481	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September Two	553	158	395	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, September Two (in shares)	'	158,096	'	'	'	'	'	'
Dividend to Seaside 88, LP, paid September Two	-4,936	0	-4,936	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C , September Two	182,575	0	182,575	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October One	436	125	311	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October One (in shares)	'	124,526	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October One	-2,948	0	-2,948	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October One (in shares)	'	0	'	'	'	'	'	-67
Common shares issued as dividend to Seaside 88, LP, For October One	3,842	2	3,840	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For October One (in shares)	'	2,050	'	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, October One	39,945	0	39,945	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Two	312	89	223	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Two (in shares)	'	89,006	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Two (in shares)	'	0	'	'	'	'	'	-47
Common shares issued as dividend to Seaside 88, LP, October Two	2,948	2	2,946	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, October Two (in shares)	'	1,586	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, October Two	-2,313	0	-2,313	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, October Two	28,413	0	28,413	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Three	281	80	201	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, October Three (in shares)	'	80,385	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Three	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, October Three (in shares)	'	0	'	'	'	'	'	-41
Shares issued as Dividend to Seaside 88, LP, October Three	2,313	1	2,312	'	'	'	'	'
Shares issued as Dividend to Seaside 88, LP, October Three (in shares)	'	1,280	'	'	'	'	'	'
Dividend to Seaside 88, LP, paid, October One	-3,842	0	-3,842	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, October Three	24,955	0	24,955	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October	10,000	5	9,995	'	'	'	'	'
Common shares issued for consulting and legal services valued, For October (in shares)	'	4,751	'	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, November One	383	109	274	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, November One (in shares)	'	109,470	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November One (in shares)	'	0	'	'	'	'	'	-47
Common shares issued as dividend to Seaside 88, LP, For November One	1,756	1	1,755	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, For November One (in shares)	'	1,092	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-1,756	0	-1,756	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, November One	28,407	0	28,407	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November Two	-1	0	-1	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, November Two (in shares)	'	0	'	'	'	'	'	-49
Shares issued in conversion of Series C Preferred Shares to Common Stock, November Two	391	112	279	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, November Two (in shares)	'	111,628	'	'	'	'	'	'
Derivative Liability - Retirement of Preferred Series C, November Two	29,302	0	29,302	'	'	'	'	'
Dividend paid to Seaside 88, LP, November Two	-1,121	0	-1,121	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two	1,121	1	1,120	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP, November Two (in shares)	'	734	'	'	'	'	'	'
Dividend paid to Seaside 88, LP, November One	-1,756	0	-1,756	'	'	'	'	'
Warrants issued to Scientific Advisory Board, For November	34,200	0	34,200	'	'	'	'	'
Common shares issued for consulting and legal services For November	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services For November (in shares)	'	3,774	'	'	'	'	'	'
Placement Agents fees related to sale of Convertible Preferred shares, For December	-165,000	0	-165,000	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December One	282	81	201	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December One (in shares)	'	80,680	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December One	0	0	0	'	'	'	'	0
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December One (in shares)	'	0	'	'	'	'	'	-35
Legal Fees related to Sale of Convertible Preferred Stock, December	-12,500	0	-12,500	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December	468	0	468	'	'	'	'	'
Common shares issued as Dividend to Seaside 88, LP, December (in shares)	'	309	'	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series C	0	0	0	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December Two	357	102	255	'	'	'	'	'
Shares issued in conversion of Series C Preferred Shares to Common Stock, December Two (in shares)	'	102,080	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP, December Two (in shares)	'	0	'	'	'	'	'	-45
Derivative liability - retirement of Series C Preferred Shares, December One	20,953	0	20,953	'	'	'	'	'
Dividend paid to Seaside 88, LP, December One	-468	0	-468	'	'	'	'	'
Shares issued to a Director for services rendered at $0.55 per share December	5,000	3	4,997	'	'	'	'	'
Shares issued to a Director for services rendered December (in shares)	'	2,581	'	'	'	'	'	'
Common shares issued for consulting and legal services For December	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services For December (in shares)	'	4,000	'	'	'	'	'	'
Derivative Liability - Issuance of Preferred Series C, December Two	24,686	0	24,686	'	'	'	'	'
Common shares issued for consulting and legal services For January	7,000	4	6,996	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January One (in shares)	'	0	'	'	'	'	'	-41
Common shares issued for conversion of Series C Preferred Shares January One	350	100	250	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares January One (in shares)	'	99,998	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One	8,992	6	8,986	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January One (in shares)	'	6,259	'	'	'	'	'	'
Derivative liability - retirement of Series C Preferred Shares For January One	22,488	0	22,488	'	'	'	'	'
Dividend paid to Seaside 88, LP January One	-8,992	0	-8,992	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	388	111	277	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares January Two (in shares)	'	110,842	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Two	-8,441	0	-8,441	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two	8,441	6	8,435	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Two (in shares)	'	5,714	'	'	'	'	'	'
Derivative liability - retirement of Series C Preferred Shares For January Two	26,329	0	26,329	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Two	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Two (in shares)	'	0	'	'	'	'	'	-47
Common shares issued for conversion of Series C Preferred Shares January Three	276	79	197	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares January Three (in shares)	'	78,797	'	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Three	7,813	5	7,808	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP For January Three (in shares)	'	5,400	'	'	'	'	'	'
Dividend paid to Seaside 88, LP January Three	-7,813	0	-7,813	'	'	'	'	'
Derivative liability - retirement ofSeries C Preferred Shares For January Three	18,502	0	18,502	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Three	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP January Three (in shares)	'	0	'	'	'	'	'	-32
Derivative liability - retirement of Series C Preferred Shares For February One	15,985	0	15,985	'	'	'	'	'
Common shares issued for consulting and legal services For January (in shares)	'	4,082	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	31,800	0	31,800	'	'	'	'	'
Common shares issued for consulting and legal services February	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	4,348	'	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares February One	241	69	172	'	'	'	'	'
Common shares issued for conversion of Series C Preferred Shares February One (in shares)	'	68,875	'	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP February One	0	0	0	'	'	'	'	'
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88, LP February One (in shares)	'	0	'	'	'	'	'	-27
Dividend paid to Seaside 88, LP February One	-7,376	0	-7,376	'	'	'	'	'
Dividend paid to Seaside 88, LP February Two	-6,002	0	-6,002	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP February Two	7,376	5	7,371	'	'	'	'	'
Common shares issued as dividend to Seaside 88, LP February Two (in shares)	'	5,172	'	'	'	'	'	'
Derivative liability - retirement of Series B Preferred Shares February Two	42	0	42	'	'	'	'	'
Common shares issued for employee stock compensation, March	60,000	71	59,929	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	71,428	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March	445,044	0	444,874	'	'	170	'	'
Series A Preferred Shares issued for employee stock compensation, March (in shares)	'	0	'	'	'	169,643	'	'
Common shares issued for consulting and legal services, For March	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	3,077	'	'	'	'	'	'
Common shares issued for consulting and legal services, April	960	1	959	'	'	'	'	'
Common shares issued for consulting and legal services, April (in shares)	'	569	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	34,800	0	34,800	'	'	'	'	'
Common shares issued for consulting and legal services, May	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services, May (in shares)	'	3,333	'	'	'	'	'	'
Common shares issued for consulting and legal services, June	6,996	3	6,993	'	'	'	'	'
Common shares issued for consulting and legal services, June (in shares)	'	3,030	'	'	'	'	'	'
Shares issued to a Director for services rendered at $0.55 per share	2,500	2	2,498	'	'	'	'	'
Shares issued to a Director for services rendered (in shares)	'	1,348	'	'	'	'	'	'
Common shares issued for consulting and legal services July	6,000	3	5,997	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	3,117	'	'	'	'	'	'
Series C Preferred Shares issued to SeaSide 88, LP, December	2,541,872	0	2,541,872	'	'	'	'	'
Series C Preferred Shares issued to SeaSide 88, LP, December (in shares)	'	0	'	'	'	'	'	714
Shares issued in payment of Debenture interest on February	665,497	571	664,926	'	'	'	'	'
Shares issued in payment of Debenture interest on February (in shares)	'	571,429	'	'	'	'	'	'
Redemption of Series C Convertible Preferred on February	-1,714,334	0	-1,714,334	'	'	'	'	'
Redemption of Series C Convertible Preferred on February (in shares)	'	'	'	'	'	'	'	-522
Common shares issued for consulting and legal services, April One	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services, April One (in shares)	'	3,175	'	'	'	'	'	'
Shares issued for Directors fees on June	11,250	5	11,245	'	'	'	'	'
Shares issued for Directors fees on June (in shares)	'	4,592	'	'	'	'	'	'
Net loss	-8,875,668	0	0	'	-8,875,668	'	'	'
Balance at Jun. 30, 2013	8,009,652	47,026	46,259,420	0	-38,299,784	2,990	0	0
Balance (in shares) at Jun. 30, 2013	'	47,026,173	'	'	'	2,990,000	'	0
Warrants issued to Scientific Advisory Board, For August	106,050	0	106,050	'	'	'	'	'
Common shares issued for consulting and legal services, August	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services valued August (in shares)	'	3,449	'	'	'	'	'	'
Common shares issued for consulting and legal services valued For September	7,000	3	6,997	'	'	'	'	'
Common shares issued for consulting and legal services valued For September (in shares)	'	3,226	'	'	'	'	'	'
Adjustment to Additional paid in Capital	83,900	'	83,900	'	'	'	'	'
Common shares issued for consulting and legal services For January	7,000	2	6,998	'	'	'	'	'
Common shares issued for consulting and legal services For January (in shares)	'	1,828	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, February	30,352	0	30,352	'	'	'	'	'
Common shares issued for consulting and legal services February	7,000	2	6,998	'	'	'	'	'
Common shares issued for consulting and legal services February (in shares)	'	1,763	'	'	'	'	'	'
Common shares issued for employee stock compensation, March	287,860	72	287,788	'	'	'	'	'
Common shares issued for employee stock compensation, March (in shares)	'	71,430	'	'	'	'	'	'
Common shares issued for consulting and legal services, For March	7,000	1	6,999	'	'	'	'	'
Common shares issued for consulting and legal services, March (in shares)	'	1,397	'	'	'	'	'	'
Warrants issued to Scientific Advisory Board, May	31,895	0	31,895	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, June One	22,902	0	22,899	'	'	3	'	'
Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued For June One	'	0	'	'	'	2,572	'	'
Common shares issued for consulting and legal services July	7,000	4	6,996	'	'	'	'	'
Common shares issued for consulting and legal services July (in shares)	'	3,627	'	'	'	'	'	'
Shares issued in payment of Debenture interest on February	2,605,716	571	2,605,145	'	'	'	'	'
Shares issued in payment of Debenture interest on February (in shares)	'	571,429	'	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 30, 2009	10,308,996	2,945	10,306,051	'	'	'	'	'
Common shares and warrants issued in connection with private placement of common stock, September 30, 2009 (in shares)	'	2,945,428	'	'	'	'	'	'
Costs associated with sale of Securities	-113,696	'	-113,696	'	'	'	'	'
Warrants issued for commissions	113,696	0	113,696	'	'	'	'	'
Placement Agents Fees related to sale of Common shares and Warrants	-618,545	0	-618,545	'	'	'	'	'
Common shares issued to round up fractional shares resulting from reverse split	0	6	-6	'	'	'	'	'
Common shares issued to round up fractional shares resulting from reverse split (in shares)	'	5,940	'	'	'	'	'	'
Common Shares issued in connection with warrant conversion, September 25, 2013	185,624	35	185,589	'	'	'	'	'
Common Shares issued in connection with warrant conversion, September 25, 2013 (in shares)	'	35,357	'	'	'	'	'	'
Shares issued for Directors fees at $2.04 per share on September 30, 2013	11,250	6	11,244	'	'	'	'	'
Shares issued for Directors fees at $2.04 per share on September 30, 2013 (in shares)	'	5,501	'	'	'	'	'	'
Common Shares issued in connection with warrant conversion, February 6, 2014	131,250	25	131,225	'	'	'	'	'
Common Shares issued in connection with warrant conversion, February 6, 2014 (in shares)	'	25,000	'	'	'	'	'	'
Warrants issued for commissions, January 24, 2014	135,062	0	135,062	'	'	'	'	'
Placement Agents Fees related to sale of Common shares and Warrants on January 24, 2014	-1,201,815	0	-1,201,815	'	'	'	'	'
Shares issued for Directors fees at $5.01 per share on March 31, 2014	11,250	2	11,248	'	'	'	'	'
Shares issued for Directors fees at $5.01 per share on March 31, 2014 (in shares)	'	2,247	'	'	'	'	'	'
Shares issued for consulting and legal services rendered from October 1, 2013 through April1, 2014	12,000	3	11,997	'	'	'	'	'
Shares issued for consulting and legal services rendered from October 1, 2013 through April1, 2014 (in shares)	'	2,593	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation at April 30, 2014	20,896	0	20,894	'	'	2	'	'
Series A Preferred Shares issued for employee stock compensation at April 30, 2014 (in shares)	'	0	'	'	'	2,572	'	'
Shares issued for consulting and legal services rendered at $3.25 per share on April 30, 2014	9,000	3	8,997	'	'	'	'	'
Shares issued for consulting and legal services rendered at $3.25 per share on April 30, 2014 (in shares)	'	2,769	'	'	'	'	'	'
Shares issued for consulting and legal services rendered at $3.27 per share on May 31, 2014	9,000	3	8,997	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation, March 31, 2014	20,379	0	192,020	'	'	21	'	'
Series A Preferred Shares issued for employee stock compensation at March 31, 2014 (in shares)	'	0	'	'	'	20,695	'	'
Series A Preferred Shares issued for employee stock compensation at May 31, 2014	'	'	20,376	'	'	3	'	'
Series A Preferred Shares issued for employee stock compensation at May 31, 2014 (in shares)	'	'	'	'	'	2,572	'	'
Shares issued for consulting and legal services rendered at $4.11 per share at June 30, 2014	9,000	2	8,998	'	'	'	'	'
Shares issued for consulting and legal services rendered at $4.11 per share at June 30, 2014 (n shares)	'	2,190	'	'	'	'	'	'
Series A Preferred Shares issued for employee stock compensation at June 30, 2014	1,830,796	'	1,830,626	'	'	170	'	'
Series A Preferred Shares issued for employee stock compensation at June 30, 2014 (in shares)	'	0	'	'	'	169,643	'	'
Shares issued for Directors fees at $4.11 per share on June 30, 2014	11,250	2	11,248	'	'	'	'	'
Shares issued for Directors fees at $4.11 per share on June 30, 2014 (in shares)	'	2,247	'	'	'	'	'	'
Net loss	-14,106,474	0	'	'	-14,106,474	'	'	'
Balance at Jun. 30, 2014	$28,604,985	$54,621	$80,953,428	$0	($52,406,258)	$3,194	$0	$0
Balance (in shares) at Jun. 30, 2014	'	54,620,993	'	'	'	3,193,079	0	0

Statement_of_Stockholders_Equi1

Statement of Stockholders' Equity [Parenthetical] (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Price per share of common stock issued for consulting services, July One	$1.93	'	'
Price per share of common stock issued for consulting services, August One	$2.03	'	'
Price per share of common stock issued for conversion of Series B Preferred stock, February One	'	'	$0.56
Price per share of common stock issued for consulting services, September One	$2.17	'	'
Price per share of common stock issued for consulting services, February One	$3.97	'	'
Price per share of common stock issued for conversion of Series C Preferred stock, November Two	'	$0.44	'
Price per share of common stock issued for conversion of Series B Preferred stock, July One	'	'	$1.11
Price per share of common stock issued for conversion of Series C Preferred stock, July One	'	$0.49	'
Price per share of common stock issued for dividend to seaside 88, July One	'	$0.49	$1.18
Price per share of common stock issued for conversion of Series B Preferred stock, July Two	'	'	$1.18
Price per share of common stock issued for conversion of Series C Preferred stock, July Two	'	$0.47	'
Price per share of common stock issued for dividend to seaside 88, July Two	'	$0.47	'
Price per share of common stock issued for consulting and legal services, July	'	$0.55	$1.26
Price per share of common stock issued for conversion of Series B Preferred stock, August One	'	'	$0.92
Price per share of common stock issued for conversion of Series C Preferred stock, August One	'	$0.42	'
Price per share of common stock issued for dividend to seaside 88, August One	'	$0.43	$0.98
Price per share of common stock issued for conversion of Series B Preferred stock, August Two	'	'	$0.95
Price per share of common stock issued for conversion of Series C Preferred stock, August Two	'	$0.48	'
Price per share of common stock issued for dividend to seaside 88, August Two	'	$0.43	$0.95
Price per share of common stock issued for consulting and legal services, August	'	$0.58	$1.14
Price per share of common stock issued for conversion of Series B Preferred stock, September One	'	'	$0.95
Price per share of common stock issued for conversion of Series C Preferred stock, September One	'	$0.58	'
Price per share of common stock issued for dividend to seaside 88, September One	'	$0.58	$0.95
Price per share of common stock issued for conversion of Series B Preferred stock, September Two	'	'	$0.94
Price per share of common stock issued for conversion of Series C Preferred stock, September Two	'	$0.52	'
Price per share of common stock issued for dividend to seaside 88, September Two	'	$0.52	$0.94
Price per share of common stock issued for consulting and legal services, September	'	$0.62	$1.07
Price per share of common stock issued for conversion of Series B Preferred stock, October One	'	'	$0.78
Price per share of common stock issued for conversion of Series C Preferred stock, October One	'	$0.54	'
Price per share of common stock issued for dividend to seaside 88, October One	'	$0.54	$0.85
Price per share of common stock issued for conversion of Series B Preferred stock, October Two	'	'	$0.69
Price per share of common stock issued for conversion of Series C Preferred stock, October Two	'	$0.53	'
Price per share of common stock issued for dividend to seaside 88, October Two	'	$0.53	$0.75
Price per share of common stock issued for conversion of Series C Preferred stock, October Three	'	$0.52	'
Price per share of common stock issued for dividend to seaside 88, October Three	'	$0.53	'
Price per share of common stock issued for consulting and legal services, October	$5.29	$0.61	$0.92
Price per share of common stock issued for conversion of Series B Preferred stock, November One	'	'	$0.78
Price per share of common stock issued for conversion of Series C Preferred stock, November One	'	$0.43	'
Price per share of common stock issued for dividend to seaside 88, November One	'	'	$0.73
Price per share of common stock issued for conversion of Series B Preferred stock, November Two	'	$0.43	$0.69
Price per share of common stock issued for dividend to seaside 88, November Two	'	$0.44	$0.64
Price per share of common stock issued for conversion of Series B Preferred stock, November Three	'	'	$0.62
Price per share of common stock issued for consulting and legal services, November	$5.14	$0.53	$0.81
Price per share of common stock issued for conversion of Series B Preferred stock, December One	'	'	$0.53
Price per share of common stock issued for conversion of Series C Preferred stock, December One	'	$0.43	'
Price per share of common stock issued for dividend to seaside 88, December One	'	$0.43	$0.57
Price per share of common stock issued for conversion of Series B Preferred stock, December Two	'	'	$0.51
Price per share of common stock issued for conversion of Series C Preferred stock, December Two	'	$0.44	'
Price per share of common stock issued for dividend to seaside 88, December Two	'	'	$0.57
Price per share of common stock issued for consulting and legal services, December	$5.01	$0.50	'
Price per share of common stock issued for conversion of Series B Preferred stock, January One	'	'	$0.51
Price per share of common stock issued for conversion of Series C Preferred stock, January One	'	$0.41	'
Price per share of common stock issued for dividend to seaside 88, January One	'	$0.41	$0.51
Price per share of common stock issued for conversion of Series B Preferred stock, January Two	'	'	$0.48
Price per share of common stock issued for conversion of Series C Preferred stock january Two	'	$0.42	'
Price per share of common stock issued for dividend to seaside 88, January Two	'	$0.42	$0.49
Price per share of common stock issued for conversion of Series C Preferred stock, January Three	'	$0.42	'
Price per share of common stock issued for dividend to seaside 88, January Three	'	$0.41	'
Price per share of common stock issued for consulting and legal services, January	$5.01	$0.49	$0.58
Price per share of common stock issued for consulting and legal services, June One	'	'	$0.61
Price per share of common stock issued for conversion of Series C Preferred stock, February One	'	$0.41	'
Price per share of common stock issued for payment of debenture interest stock, February	$0.48	$0.48	'
Price per share of common stock issued for dividend to seaside 88, February One	'	$0.41	'
Price per share of common stock issued for conversion of Series B Preferred stock, February Two	'	'	$0.69
Price per share of common stock issued for dividend to seaside 88, February Two	'	'	$0.69
Price per share of common stock issued for consulting and legal services, February	'	$0.46	$0.77
Price per share of common stock issued for employee stock compensation, March One	'	'	$0.73
Price per share of common stock issued for employee stock compensation, March Two	'	$0.48	$0.73
Price per share of common stock issued for conversion of Series B Preferred stock, March One	'	'	$0.64
Price per share of common stock issued for dividend to seaside 88, March One	'	'	$0.64
Price per share of common stock issued for conversion of Series B Preferred stock, March Two	'	'	$0.63
Price per share of common stock issued for dividend to seaside 88, March Two	'	'	$0.64
Price per share of common stock issued for consulting and legal services, March	$3.83	$0.65	$0.78
Price per share of common stock issued for director services rendered, March	$5.01	$0.53	'
Price per share of common stock issued for conversion of Series B Preferred stock, April One	'	'	$0.61
Price per share of common stock issued for dividend to seaside 88, April One	'	'	$0.61
Price per share of common stock issued for conversion of Series B Preferred stock, April Two	'	'	$0.51
Price per share of common stock issued for dividend to seaside 88, April Two	'	'	$0.54
Price per share of common stock issued for consulting and legal services, April	'	'	$0.63
Price per share of common stock issued for conversion of Series B Preferred stock, May One	'	'	$0.50
Price per share of common stock issued for dividend to seaside 88, May One	'	'	$0.51
Price per share of common stock issued for consulting and legal services, May	'	'	$0.67
Price per share of common stock issued for conversion of Series C Preferred stock, June One	'	'	$0.49
Stock Issued During September For Director Services Rendered Price Per Share	$2.04	'	'
Stock Issued During December For Director Services Rendered Price Per Share	$5.07	$0.55	'
Stock Issued During April For Consulting And Legal Services Two Price Per Share	$3.25	'	'
Stock Issued During May For Consulting And Legal Services Two Price Per Share	$3.27	'	'
Stock Issued During June For Consulting And Legal Services Four Price Per Share	$4.11	'	'
Stock Issued During Period For Employee Stock Compensation Price Per Share For June One	$4.03	'	'
Stock Issued During Period For Director Fees Price Per Share June	$4.11	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($14,106,474)	($8,875,668)	($6,207,207)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Preferred shares issued as compensation	2,123,017	445,044	982,867
Common shares and warrants issued for services	434,859	163,710	253,873
Common shares issued for interest	2,605,716	665,497	'
Warrants granted to scientific advisory board	199,849	141,600	211,197
Depreciation	203,234	210,877	210,877
Amortization	8,775	8,774	8,776
Change in fair value of derivative liability	1,948,058	1,249,335	172,251
Amortization of deferred financing expenses	0	0	0
Discount convertible debentures	569,495	0	0
Beneficial conversion feature of convertible debentures	0	0	0
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses	-56,492	-284,206	18,120
Other current assets	-150,000	0	'
Deferred expenses	0	0	0
Accounts payable - trade	113,188	24,900	158,829
Accounts payable - related parties	48,109	344,886	-97,274
Accrued expenses	-112,521	107,479	69,705
Accrued payroll to officers and related payroll tax expense	0	0	'
NET CASH USED IN OPERATING ACTIVITIES	-6,333,625	-5,797,772	-4,217,986
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Security Deposit	0	-1,000,000	'
Purchase of property and equipment	-5,231,094	-64,931	-23,352
Purchase of trademark	0	0	-35,200
NET CASH USED IN INVESTING ACTIVITIES	-5,231,094	-1,064,931	-58,552
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of Convertible Debentures	5,000,000	6,000,000	'
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs	28,602,740	0	0
Proceeds from exercise of warrants	735,626	0	'
NET CASH PROVIDED BY FINANCING ACTIVITIES	34,338,366	6,510,963	9,327,500
NET CHANGE IN CASH	22,773,647	-351,740	5,050,962
Cash at beginning of period	13,923,245	14,274,985	9,224,023
Cash at end of period	36,696,892	13,923,245	14,274,985
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:	'	'	'
Interest paid	0	0	0
Income tax paid	0	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'	'
Common stock issued for services rendered	434,859	163,710	253,873
Common stock for interest	2,605,716	665,497	'
Preferred stock issued as compensation	2,123,017	445,044	982,867
Stock options issued to the officers as compensation	0	0	0
Stock warrants granted to scientific advisory board	199,849	141,600	211,197
Stock warrants granted to brokers	0	0	0
Common stock issued for interest on debentures	0	0	0
Shares of common stock issued in connection with debenture offering	0	0	0
Common stock issued upon conversion of convertible debentures	0	0	0
Debt discount related to beneficial conversion feature of convertible debt	'	0	0
Stock Warrants issued in connection with Private Placement	0	0	0
Common stock issued for accounts payable	0	0	0
Common stock issued for equipment	0	0	0
Related Party [Member]	'	'	'
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses	-162,438	0	'
Series B Convertible Preferred Stock [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of Convertible Preferred stock, net	'	'	7,002,500
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'	'
Common stock issued upon conversion of Preferred Stock	'	'	7,920,630
Common stock issued for dividends on Preferred Stock	'	'	79,467
Series C Convertible Preferred Stock [Member]	'	'	'
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of Convertible Preferred stock, net	'	510,963	2,325,000
NON CASH FINANCING AND INVESTING ACTIVITIES:	'	'	'
Common stock issued upon conversion of Preferred Stock	'	3,028,464	298,472
Common stock issued for dividends on Preferred Stock	'	$90,108	'

Organization_and_Nature_of_Bus

Organization and Nature of Business	12 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 - Organization and Nature of Business
	NanoViricides, Inc. was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. and was organized for the purpose of conducting Internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling the Company as a Nevada corporation.  On May 12, 2005, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.
	On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  NanoViricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.
	Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 22,857,143 newly issued shares of ECMM common stock resulting in an aggregate of 28,571,429 shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of 1,143 shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.
	As a result of the Exchange transaction the former NVI stockholders held approximately 80% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 01, 2005, and represent the operations of NVI.
	On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.   Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  The Company is considered a development stage company at this time.
	NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a development stage company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary licenses in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.
	On February 15, 2010 the Company approved an Additional License Agreement with TheraCour Pharma, Inc. (“TheraCour”).  Pursuant to the exclusive Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares of the Company’s Series A Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of three and one half shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends; have no liquidation preference and are not to be amended without the holders approval. The 2,000,000 shares were valued at $7,000.
	We focus our research and clinical programs on specific anti-viral therapeutics. Our anti-viral therapeutics, that we call “nanoviricides®” are designed to look to the virus like the native cell surface to which it binds. Since these binding sites for a given virus do not change despite mutations and other changes in the virus, we believe that our drugs will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-binding portion of the nanoviricide is engineered appropriately.
	NanoViricides, Inc. is the first in the world in the entire field of nanomedicines to have developed a nanomedicine drug that can be administered orally (by mouth). Our oral anti-influenza drug candidate, NV-INF-2, has shown extremely high broad-spectrum effectiveness against two different influenza A viruses in animal models, in our FluCide™ program. We are also developing a highly effective injectable anti-influenza drug, NV-INF-1, in this program. The Company held a pre-IND Meeting with the US FDA for its clinical drug candidate, NV-INF-1, in March, 2012. The Company is developing this injectable drug (NV-INF-1) for hospitalized patients with severe influenza, including immuno-compromised patients. The Company believes that this drug may also be usable as a single-dose injection in a medical office for less severe cases of influenza. Both of these anti-influenza therapeutic candidates are “broad-spectrum”, i.e. they are expected to be effective against most if not all types of influenzas including the recently discovered novel strain of H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas (HPI/HPAI), Epidemic Influenzas such as the 2009 “swine flu” H1N1/A/2009, and Seasonal Influenzas including the recent H3N2 influenza. The Company has already demonstrated that our anti-influenza drugs have significantly superior activity when compared to oseltamivir (Tamiflu®) against two unrelated influenza A subtypes, namely, H1N1 and H3N2 in a highly lethal animal model. Both of these drug candidates can be used as prophylactics to protect at-risk personnel such as health-care workers and immediate family members and caretakers of a patient.
	The Company is also developing an anti-HIV drug. The drug candidates in this HIVCide™ program were found to have effectiveness equal to that of a triple drug HAART cocktail therapy in the standard humanized SCID-hu Thy/Liv mouse model. Moreover, the nanoviricides were long acting. Viral load suppression continued to hold for more than four weeks after stopping HIVCide treatment. The Company believes that this strong effect and sustained effect together indicate that a HIVCide can be developed as a single agent that would provide “Functional Cure” from HIV/AIDS. The Company believes that substantially all HIV virus can be cleared upon HIVCide treatment, except the integrated viral genome in latent cells. This would enable discontinuation of treatment until HIV reemerges from the latent reservoir, which may be several months without any drugs. Moreover, the Company believes that this therapy would also minimize the chances of HIV transmission. The Company is currently optimizing the anti-HIV drug candidates. These drug candidates are effective against both the R5 and X4 subtypes of HIV-1 in cell cultures. The Company believes that these drug candidates are “broad-spectrum”, i.e. they are expected to be effective against most strains and mutants of HIV, and therefore escape of mutants from our drugs is expected to be minimal.
	The Company is also developing broad-spectrum eye drops that are expected to be effective against a majority of the viral infections of the external eye. Most of these viral infections are from adenoviruses or from herpes viruses. The Company has shown excellent efficacy of its drug candidates against EKC (adenoviral epidemic kerato-conjunctivitis) in an animal model. In addition, the anti-HSV drug candidates have shown excellent efficacy in cell culture studies. The Company is also developing a skin cream formulation for the treatment of herpes cold sores or genital warts. Further, the Company is developing a broad-spectrum drug against Dengue viruses that is expected to be useful for the treatment of any of the four major serotypes of dengue viruses, including in severe cases of dengue (DSS) and dengue hemorrhagic fever (DHF). DSS and DHF are thought to be caused by prior antibodies against dengue that a patient’s body creates to fight a second unrelated dengue infection, and the second virus uses these antibodies effectively to hitch a ride into human cells, thereby causing a more severe infection than in naive patients. In addition to these six drugs in development, the Company also has research programs against Rabies virus, Ebola and Marburg viruses, and others. To date, the Company does not have any commercialized products. The Company continues to add to our existing portfolio of products through our internal discovery and clinical development programs and also seeks to do so through an in-licensing strategy.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2 - Summary of Significant Accounting Policies
	The Management of the Company is responsible for the selection and use of appropriate accounting policies and the appropriateness of accounting policies and their application. Critical accounting policies and practices are those that are both most important to the portrayal of the Company’s financial condition and results and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. The Company’s significant and critical accounting policies and practices are disclosed below as required by generally accepted accounting principles.
	Basis of Presentation
	The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
	Fiscal Year End
	The Company elected June 30th as its fiscal year end date upon its formation.
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	The Company’s significant estimates include the fair value of financial instruments; the carrying value, recoverability and impairment of long-lived assets, including the values assigned to and estimated useful lives of property and equipment and trade mark, and underlying assumptions to estimate the fair value of derivative financial instruments; income tax rate, income tax provision and valuation allowance of deferred tax assets. These significant accounting estimates bear the risk of change due to the fact that there are uncertainties attached to those estimates and certain estimates are difficult to measure or value.
	Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
	Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, if deemed appropriate, those estimates are adjusted accordingly.
	Actual results could differ from those estimates.
	Reclassification
	Certain reclassifications have been made in prior year’s financial statements to conform to the financial presentation used in the current year. These reclassifications from General and Administrative Expenses to Research and Development expenses had no effect on total operating expenses, operating loss or net loss for any period presented.
	Derivatives and Fair Value of Financial Instruments
	The Company applied paragraph 815-10-05-4 of the FASB Accounting Standards Codification to the Series B Convertible Debenture issued January 15, 2013.  Based on the guidance in paragraph 815-10-05-4 of the FASB Accounting Standards Codification the Company concluded these instruments were required to be accounted for as derivatives as of January 15, 2013.  The Company records the fair value of the preferred stock that are classified as derivatives on its balance sheet at fair value with changes in the values of these derivatives reflected in the consolidated statements of operations as “Gain (loss) on derivative liabilities.”  These derivative instruments are not designated as hedging instruments under paragraph 815-10-05-4 of the FASB Accounting Standards Codification and are disclosed on the balance sheet under Derivative Liabilities.
	The Company follows paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments and paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:
		Level  1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
		Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
		Level 3	Pricing inputs that are generally observable inputs and not corroborated by market data.
	Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
	The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepayments and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.
	The Company’s Level 3 financial liabilities consist of the Series B convertible debenture issued January 15, 2013 for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. We have valued the automatic conditional conversion, re-pricing/down-round, change of control; default and follow-on offering provisions using a lattice model, with the assistance of a valuation consultant, for which management understands the methodologies. These models incorporate transaction details such as Company stock price, contractual terms, maturity, risk free rates, as well as assumptions about future financings, volatility, and holder behavior as of issuance and June 30, 2014. The primary assumptions include: projected annual volatility of 92%-95%; the follow-on securities purchase option; the conversion feature as a percentage of Market; automatic/conditional conversions; market price trigger events.
	As of June 30, 2014, the Company’s derivative financial instruments are embedded derivatives associated with certain of the Company’s unsecured convertible debentures. The Company’s Series B convertible debenture issued to five (5) unrelated investors is a hybrid instrument, which warrants separate accounting as a derivative instrument. The embedded derivative feature has been bifurcated from the debt host contract, referred to as the Derivative Liability”, which resulted in a reduction of the initial carrying amount (as unamortized discount) of the Debentures. The unamortized discount is amortized to interest expense using the effective interest method over the life of the Debentures. The embedded derivative feature includes the conversion feature within the notes and an early redemption option.  The compound embedded derivatives within the convertible Debentures have been recorded at fair value at the date of issuance; and are marked-to-market each reporting period with changes in fair value recorded to the Company’s statement of operations as Change in fair value of derivative liabilities.
	The Series B Convertible Debenture were valued at 6/30/14. The following assumptions were used for the valuation of the embedded derivative:
		-	The balance of the Series B Convertible Debenture as of 6/30/14 is $6,000,000 following the interest payment on 6/30/14;
		-	The underlying stock price was used as the fair value of the common stock;
		-	The stock price increased from $0.9143 to $1.2086 which significantly increased the warrant value with the $1.00 exercise price (from out to in the money);
		-	The projected annual volatility was based on the Company historical volatility:
	3/31/14		95	%
	6/30/14		92	%
		-	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;
		-	The company would redeem the debentures projected initially at 0% of the time and increase monthly by 1.0% to a maximum of 20.0% (from alternative financing being available for a Redemption event to occur);
		-	The Holder would automatically convert the interest if the company was not in default;
		-	The Holder would automatically convert the debenture at maturity if the registration was effective and the company was not in default.
	Derivative Valuation – Additional Redemption and Interest Warrants
	The Redemption and Interest Warrants potentially issued were valued as of 6/30/14 (for all scenarios based on the lattice projected stock prices and historical volatility of the company) and the following assumptions were used for the valuation of the derivative:
		-	The stock price would fluctuate with the Company projected volatility;
		-	The projected volatility curve for each valuation period was based on the historical volatility of the Company (see previous section);
		-	The Holder would exercise the warrant at maturity if the stock price was above the exercise price;
		-	The Holder would exercise the warrant at target prices starting at the greater of 2 times the exercise price or the stock price; and lowering such target as the warrants approached maturity.
		-	In this period no warrants were issued or exercised.
	Based on these management assumptions, the fair value of the Redemption and Interest Warrants (“Additional Warrants” or “Warrants”) derivative liability as of the projected issuance dates. Redemption Warrants assumed issuance as of the valuation dates and the Interest Warrants scenario valuations assume issuance 1/15/15.
	Series B Convertible Debenture		6,000,000		6,000,000
	Derivative Value		3,824,987		5,699,703
	Mark to Market		-3,752,933		1,874,716
	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the fiscal year ended June 30, 2014:
			Fair Value Measurements
			Using Level 3 Inputs
				Derivative
				Liabilities			Totals
	Balance, June 30, 2011			17,519			17,519
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss			-172,245			-172,245
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements			1,233,424			1,233,424
	Transfers in and/or out of Level 3
	Balance, June 30, 2012			1,078,698			1,078,698
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss			-1,249,335			-1,249,335
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements			3,922,282			3,922,282
Transfers in and/or out of Level 3			-			-
Balance, June 30, 2013		$	3,751,645		$	3,751,645
Included in Net (Income) Loss			1,948,058			1,948,058
Included in Other Comprehensive Income
Purchases, Issuances and Settlements			-			-
Transfers in and/or out of Level 3			-			-
Balance, June 30, 2014		$	5,699,703		$	5,699,703
The fair value of the derivatives was $2,735,310 as of January 15, 2013 upon issuance and was $5,699,703 at June 30, 2014.
The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring.  Accordingly, changes to these assessments could materially affect the valuation.
Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’'s-length transactions unless such representations can be substantiated.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Level 3 Financial Liabilities – Derivative Warrant Liabilities
The Company uses Level 3 of the fair value hierarchy to measure the fair value of the derivative liabilities and revalues its derivative warrant liability at every reporting period and recognizes gains or losses in the statements of operations that are attributable to the change in the fair value of the derivative warrant liability.
Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative Liabilities:
		As of June 30, 2014
		Carrying		Fair Value Measurements Using
		Value		Level 1		Level 2	Level 3	Total
Liabilities
Derivative Liabilities associated with
Series B Convertible Debentures		5,699,703					5,699,703	5,699,703
Total Derivative Liabilities		5,699,703					5,699,703	5,699,703
Carrying Value, Recoverability and Impairment of Long-Lived Assets
The Company has adopted paragraph 360-10-35-17 of the FASB Accounting Standards Codification for its long-lived assets. The Company’s long-lived assets, which include property and equipment and trade mark and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.
The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates acquired assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events.
The impairment charges, if any, is included in operating expenses in the statements of operations.
The Company determined that there were no impairments of long-lived assets as of June 30, 2014 or 2013.
Cash and Cash Equivalents
The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents.
Property and Equipment
Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets (generally five (5) to seven (7) years), or lease term for leasehold improvement, using the straight-line method. Expenditures for major additions and betterments are capitalized.  Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
Intangible Assets Other Than Goodwill
The Company has adopted Subtopic 350-30 of the FASB Accounting Standards Codification for intangible assets other than goodwill. Under the requirements, the Company amortizes the acquisition costs of intangible assets other than goodwill on a straight-line basis over or their estimated useful lives, the terms of the exclusive licenses and/or agreements, or the terms of legal lives of the patents, whichever is shorter. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Research and Development
Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.
Stock-Based Compensation for Obtaining Employee Services
The Company accounts for its stock based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of section 718-10-30 of the FASB Accounting Standards Codification. Pursuant to paragraph 718-10-30-6 of the FASB Accounting Standards Codification, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.  The ranges of assumptions for inputs are as follows:
⋅	Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. Pursuant to paragraph 718-50-S99-1, it may be appropriate to use the simplified method, if (i) A company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) A company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) A company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as the company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.
⋅	Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
⋅	Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments.
⋅	Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments.
The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award.
Equity Instruments Issued to Parties other than Employees for Acquiring Goods or Services
The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of section 505-50-30 of the FASB Accounting Standards Codification (“FASB ASC Section 505-50-30”).
Pursuant to FASB ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows:
⋅	Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
⋅	Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
⋅	Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments.
⋅	Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments.
Pursuant to ASC paragraph 505-50-25-7, if fully vested, non-forfeitable equity instruments are issued at the date the grantor and grantee enter into an agreement for goods or services (no specific performance is required by the grantee to retain those equity instruments), then, because of the elimination of any obligation on the part of the counterparty to earn the equity instruments, a measurement date has been reached. A grantor shall recognize the equity instruments when they are issued (in most cases, when the agreement is entered into). Whether the corresponding cost is an immediate expense or a prepaid asset (or whether the debit should be characterized as contra-equity under the requirements of paragraph 505-50-45-1) depends on the specific facts and circumstances. Pursuant to ASC paragraph 505-50-45-1, a grantor may conclude that an asset (other than a note or a receivable) has been received in return for fully vested, non-forfeitable equity instruments that are issued at the date the grantor and grantee enter into an agreement for goods or services (and no specific performance is required by the grantee in order to retain those equity instruments). Such an asset shall not be displayed as contra-equity by the grantor of the equity instruments. The transferability (or lack thereof) of the equity instruments shall not affect the balance sheet display of the asset. This guidance is limited to transactions in which equity instruments are transferred to other than employees in exchange for goods or services. Section 505-50-30 provides guidance on the determination of the measurement date for transactions that are within the scope of this Subtopic.
Pursuant to ASC paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a stock option that the counterparty has the right to exercise expires unexercised.
Pursuant to ASC paragraph 505-50-30-S99-1, if the Company receives a right to receive future services in exchange for unvested, forfeitable equity instruments, those equity instruments are treated as unissued for accounting purposes until the future services are received (that is, the instruments are not considered issued until they vest). Consequently, there would be no recognition at the measurement date and no entry should be recorded.
Related Parties
The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.
Pursuant to Section 850-10-20 the related parties include a. affiliates of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved b.  description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Commitment and Contingencies
The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
Income Tax Provision
The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income and Comprehensive Income in the period that includes the enactment date.
The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements.  Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty (50) percent likelihood of being realized upon ultimate settlement.  Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.  The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.
Uncertain Tax Positions
The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the fiscal year ended June 30, 2014, 2012, or 2011.
The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary.
Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Concentrations of Risk
Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Net Income (Loss) per Common Share
Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the Fiscal		For the Fiscal		For the Fiscal
		Year		Year		Year
		Ended		Ended		Ended
		June 30, 2014		June 30, 2013		June 30, 2012
Stock options
Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.10 per share expiring ten (10) years from the date of issuance		535,714		535,714		535,714
Sub-total: stock options		535,714		535,714		535,714
Warrants
Warrants issued from June 15,2006 to October 1, 2007 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28,2014		520,286		520,286		520,286
Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28,2014		466,486		466,486		466,486
Warrants issued from June 15, 2008 through May 15,2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28,2014		211,429		211,429		211,429
Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		561,628		568,771		568,771
Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		1,437,871		1,437,871		1,437,871
Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015		65,714		65,714		65,714
Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016		68,571		68,571
Warrants issued from August 16, 2013 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017		68,571		68,571
Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through March 31, 2014		2,802,928
Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017		17,143
Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018		58,910
Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017		17,143
Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019		2,479,935
Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019		76,306
Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018		17,143
Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018		17148
Sub-total: warrants		8,887,212		3,407,699		3,270,557
Total potentially outstanding dilutive common shares		9,422,926		3,943,413		3,806,271
In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
At June 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,408,451 based upon the Selling price of the Company’s common stock on June 30, 2014 of $4.26. At June 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,142,858.
The Company has also issued 3,193,079 of $0.001 par value Convertible Preferred A shares to investors and others. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At June 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 11,175,776.
Cash Flows Reporting
The Company adopted paragraph 230-10-45-24 of the FASB Accounting Standards Codification for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB Accounting Standards Codification to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.  The Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB Accounting Standards Codification.
Subsequent Events
The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements are issued.  Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.
Recently Issued Accounting Pronouncements
In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update change the requirements for reporting discontinued operations in Subtopic 205-20.
Under the new guidance, a discontinued operation is defined as a disposal of a component or group of components that is disposed of or is classified as held for sale and “represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results.” The ASU states that a strategic shift could include a disposal of (i) a major geographical area of operations, (ii) a major line of business, (iii) a major equity method investment, or (iv) other major parts of an entity. Although “major” is not defined, the standard provides examples of when a disposal qualifies as a discontinued operation.
The ASU also requires additional disclosures about discontinued operations that will provide more information about the assets, liabilities, income and expenses of discontinued operations. In addition, the ASU requires disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation in the financial statements.
The ASU is effective for public business entities for annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of the ASU would not have a material effect on the accompanying financial statements.
In May 2014, the FASB issued the FASB Accounting Standards Update No. 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”).
This guidance amends the existing FASB Accounting Standards Codification, creating a new Topic 606, Revenue from Contracts with Customer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
To achieve that core principle, an entity should apply the following steps:
	1	Identify the contract(s) with the customer
	2	Identify the performance obligations in the contract
	3	Determine the transaction price
	4	Allocate the transaction price to the performance obligations in the contract
	5	Recognize revenue when (or as) the entity satisfies a performance obligations
The ASU also provides guidance on disclosures that should be provided to enable financial statement users to understand the nature, amount, timing, and uncertainty of revenue recognition and cash flows arising from contracts with customers.  Qualitative and quantitative information is required about the following:
Contracts with customers – including revenue and impairments recognized, disaggregation of revenue, and information about contract balances and performance obligations (including the transaction price allocated to the remaining performance obligations)
	1	Significant judgments and changes in judgments – determining the timing of satisfaction of performance obligations (over time or at a point in time), and determining the transaction price and amounts allocated to performance obligations
	2	Assets recognized from the costs to obtain or fulfill a contract.
ASU 2014-09 is effective for periods beginning after December 15, 2016, including interim reporting periods within that reporting period for all public entities.  Early application is not permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage. The Company adopted this guidance from June 30, 2014.
In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation—Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.  The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition.  The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015.  Earlier adoption is permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements— Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted. The amendments of the ASU would not have a material effect on the accompanying financial statements
Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Financial_Condition

Financial Condition	12 Months Ended
	Jun. 30, 2014
Financial Conditons Disclosure [Abstract]	'
Financial Conditons Disclosure [Text Block]	'
	Note 3 - Financial Condition
	As reflected in the consolidated financial statements, the Company had a deficit accumulated during the development stage at June 30, 2014 and had a net loss and net cash used in operating activities for the fiscal year then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of June 30, 2014 the Company had a cash and cash equivalent of $36,696,892.
	While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities.
	On February 1, 2013 the Company consummated an offering (the “Offering”) in the aggregate amount of $6,000,000 for its Unsecured 8% Coupon Series B Convertible Debenture (the “Debentures”) to four equity investors comprised of private, family investment offices and a charitable foundation. The Debentures are due on January 31, 2017 (the “Maturity Date”) and are convertible into restricted shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $3.50 per share of Common Stock. Additional interest is to be paid to the subscribers in Common stock of the Company. In accordance with ASC 470-20, the Company separately accounted for the conversion feature and recognized each component of the transaction separately. As a result, the Company recognized a discount on the convertible debenture in the amount of $1,367,655 and reports the face value of the Convertible Debentures net of such discount. The Discount is amortized over the life of the Convertible Debentures which mature on February 1, 2017. The Company recognized the discount as a derivative liability, and in accordance with the ASC, values the derivative liability each reporting period to market. See Note 2- Summary of Significant Accounting Policies - Derivatives and Fair Value of Financial Instruments
	On September 12, 2013, post reverse -split the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”), and the Company raised gross proceeds of $10,308,996 before estimated expenses of the Offering of approximately $618,540, which includes placement agent and attorneys’ fees. The Company issued 2,945,428 Units. On September 25, 2013 certain of these Unit Holders exercised 35,357 Warrants to purchase 35,357 shares of the Company’s common stock, par value $0.001 per share, for gross proceeds of $185,624. On January 21, 2014 and February 6, 2014 certain of these Unit Holders exercised 75,000 and 25,000 Warrants to respectively purchase 75,000 and 25,000 shares of the Company’s common stock, par value $0.001 per share, for gross proceeds of $393,750 and $131,750 respectively.
	On January 21, 2014, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $5.25 (“Purchase Price”) per Unit. The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Company’s stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Company’s stock on Friday, January 17, 2014.  Each Unit consisted of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $6.05 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”). The Warrants are exercisable immediately and expire five years after issuance.
	On January 24, 2014, the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”) of 3,815,285 shares of Common Stock and 2,479,935 Warrants, and the Company raised gross proceeds of $20,030,206 before estimated expenses of the Offering of approximately $1,200,000, which includes placement agent fees but does not include and attorneys’ fees and other expenses. The Company intends to use the proceeds for general business purposes and expects that it will be able to accelerate the development of its drug candidate pipeline with this additional funding.
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenturehad been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 shall be calculated on a per diem basis from the Closing Date.
	On September 5, 2014, NanoViricides, Inc. (the “Company”) accepted notices to exercise warrants for the purchase of an aggregate of 2,136,655 shares of the Company’s common stock at the exercise price of $3.50 per share for aggregate proceeds of $7,478,292.50. On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009, as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. As of August 15, 2014, any Registered Warrants as specified above and not previously exercised have expired.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 4 –Related Party Transactions
	Related Parties
	Related parties with whom the Company had transactions are:
	Related Parties	Relationship
	Anil R. Diwan	Chairman, President, significant stockholder and director
	Eugene Seymour	CEO, Significant shareholder, Director
	TheraCour Pharma, Inc.	An entity owned and controlled by significant stockholder
	InnoHaven, LLC	An entity owned and controlled by significant stockholder
	Milton Boniuk, MD	Director and significant stockholder
	Fixed Assets
		June 30, 2014		June 30, 2013
	During the reporting period, InnoHaven, LLC, acquired fixed assets on behalf of the Company from third party vendors behalf of the Company at 1 Controls Drive, Shelton, Ct	$	4,500,000		-
	During the reporting Period, Thera Cour Pharma, Inc acquired fixed assets on behalf of the Company from third party vendors	$	528,720		-
	Account Payable – Related Party
		June  30, 2014		June 30, 2013
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. . In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc on the reporting date was	$	758,676	$	710,567
	The Accounts payable were offset by contractual advances of	$	709,221		546,783
	Net Account Payable to related party	$	49,455	$	163,784
	Research and Development Costs Paid to Related Parties
		June 30, 2014		June 30, 2013
	Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. As of June 30, 2014, pursuant to its license agreement, the Company has paid a security advance of $709,221 to and held by TheraCour Pharma, Inc. which is reflected in Prepaid Expenses. No royalties are due TheraCour from the Company’s inception through June 30, 2014.	$	2,611,754	$	1,988,046
	Long-Term Debentures Payable – Directors
		June 30, 2014		June 30, 2013
	On February 1, 2013, the Company raised $4M from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal. The warrants are priced at $3.50 and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.	$	4,000,000	$	4,000,000
	Repayments from inception to date		-		-
	Remaining balance		4,000,000		4,000,000
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 shall be calculated on a per diem basis from the Closing Date.		5,000,000		5,000,000
	Repayments from inception to date		-		-
	Remaining balance		5,000,000		5,000,000
		$	9,000,000	$	9,000,000
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. . In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf (4) make royalty payments (calculated as a percentage of net sales of the licensed drugs) of 15% to TheraCour Pharma, Inc. (5) agreed that TheraCour Pharma, Inc. retains the exclusive right to develop and manufacture the licensed drugs. TheraCour Pharma, Inc. agreed that it will manufacture the licensed drugs exclusively for NanoViricides, and unless such license is terminated, will not manufacture such product for its own sake or for others.

Concentrations

Concentrations	12 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	Note 5 - Concentrations
	Vendor purchase concentrations for December 31, 2014 and 2013 are as follows:
		Net Purchases								Accounts Payable
		For the years ended June 30								As of June 30,
		2014				2013				2014				2013
	TheraCour Pharma, Inc		3,140,474	36.2	%		1,988,046	30.2	%		758,676	75.6	%		710,567	72.97	%
	Kard Scientific, Inc.		314,156	3.6	%		1,035,983	15.7	%		123,570	10.9	%		123,132	12.64	%
	Total		3,454,630	39.9	%		3,024,029	45.9	%		882,246	77.7	%		833,699	85.6	%

Property_and_Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 6 - Property and Equipment
	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
		June 30, 2014		June 30, 2013
	GMP Facility	$	3,099,780	$	397,407
	Office Equipment		30,048		30,048
	Furniture and Fixtures		1,400		1,400
	Lab Equipment		3,605,514		1,076,793
	Total Property and Equipment		6,736,742		1,505,648
	Less Accumulated Depreciation		-1,239,986		-1,036,752
	Property and Equipment, Net	$	5,496,756	$	468,896
	Depreciation expense amounted to $203,234, $210,877 and $210,877 for the fiscal year ended June 30, 2014, 2013 and 2012, respectively.

Trademark_and_Patents

Trademark and Patents	12 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 7 – Trademark and Patents
	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:
		June 30, 2014		June 30, 2013
	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-50,696		-41,921
	Trademarks and Patents, Net	$	408,258	$	417,033
	Amortization expense amounted to $8,774, $8,776 and $8,774, for the fiscal years ended June 30, 2014, 2013 and 2012, respectively.

Equity_Transactions

Equity Transactions	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 8 - Equity Transactions
	On September 3, 2013, effective September 10, 2013, NanoViricides, Inc. filed a Certificate of Change to its Articles of Incorporation pursuant to Section 78.209 of the Nevada Revised Statutes (the “Amendment”). The Amendment effectuated a reverse stock split of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) by simultaneously decreasing the number of the Registrant’s authorized and outstanding capital stock on a basis of 1 for 3.5 shares (the “Split”). All share amounts and per share amounts have been retroactively restated to reflect this reverse stock split.
	Fiscal Year Ending June 30, 2012 Transactions
	On November 2, 2011, the Company entered into a Securities Purchase Agreement (the “Agreement”) with Seaside, relating to the offering and sale (the “Offering”) of up to 142,857 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”) at the purchase price of $35.00 per share (the “Purchase Price”). On November 2, 2011, Seaside purchased an initial 71,429 shares of the Series B Preferred Stock for an aggregate purchase price of $2,500,000 (the “Initial Closing”). Seaside purchased the remaining 71,429 shares of the Series B Preferred Stock for the purchase price of $2,500,000 (the “Subsequent Closing”). 11,429 shares of the Series B Preferred Stock automatically converted into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at each of the Initial Closing and the Subsequent Closing and every fourteenth day thereafter at a conversion price equal to the Purchase Price divided by the lower of (i) the daily volume weighted average of actual trading prices of the Common Stock on the trading market (the “VWAP”) for the ten consecutive trading days immediately prior to a conversion date multiplied by 0.85 and (ii) the VWAP for the trading day immediately prior to a conversion date multiplied by 0.88. In the event that the conversion price does not equal or exceed $0.70 (the “Floor”), as calculated with respect to any subsequent conversion date, then such conversion will not occur and the shares not converted on that date will be added to the conversion on the following conversion date.
	The Agreement contains representations and warranties and covenants for each party, which must be true and have been performed at each closing. Additionally, the Company has agreed to indemnify and hold harmless Seaside against certain liabilities in connection with the issuance and sale of the Series B Preferred Stock under the Agreement.
	The conversion price per share for the Initial Closing was $0.223307, and the Company raised gross proceeds from the offering of $2,500,000, before estimated offering expenses of approximately $200,000 which includes placement agent and attorneys’ fees. The conversion price per share for the Subsequent Closing was $0.15936 and the Company raised gross proceeds from the offering of $2,500,000, before estimated offering expenses of approximately $200,000 which includes placement agent and attorneys’ fees.
	On June 28, 2012, the Company entered into an additional Securities Purchase Agreement (the “Agreement”) with Seaside, relating to the offering and sale (the “Offering”) of up to 1,429 shares of the Company’s Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”) at the purchase price of $3,500.00 per share (the “Purchase Price”). On June 28, 2012, Seaside purchased an initial 714 shares of the Series C Preferred Stock for an aggregate purchase price of $2,500,000 (the “Initial Closing”). Following the Initial Closing, Seaside will purchase the remaining 714 shares of the Series C Preferred Stock for the purchase price of $2,500,000 (the “Subsequent Closing”).
	The conversion price per share for the Initial Closing of the Series C Preferred Stock was $.14052 and the Company raised gross proceeds from the offering of $2,500,000 before estimated offering expenses of approximately $200,000, which includes placement agents and attorneys’ fees.
	The Offerings were made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-165221), which was declared effective by the Securities and Exchange Commission on April 29, 2010. The Company, pursuant to Rule 424(b) under the Securities Act of 1933, filed with the Securities and Exchange Commission a prospectus supplement relating to the Offering.
	In connection with the Offering, pursuant to a Placement Agency Agreement entered into by and between Midtown and the Company, as amended by an Underwriter Agent Agreement Amendment No. 1, dated March 28, 2011 (as amended, the “Placement Agency Agreement”), the Company paid Midtown a cash fee representing 6% of the gross purchase price paid by Seaside for the Series B Preferred Stock.
	Unregistered Securities
	In August, 2011, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $4.935 per share expiring in February, 2015.  These warrants were valued at $56,400 and recorded as consulting expense.
	In November, 2011, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $3.318 per share expiring in November, 2015.  These warrants were valued at $56,400 and recorded as consulting expense.
	In February, 2012, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $3.815 per share expiring in February, 2016.  These warrants were valued at $51,000 and recorded as consulting expense.
	In March, 2012 the Company authorized the issuance of 169,643 shares of its Series A Preferred stock $.001 par value with a restrictive legend pursuant to existing employment agreements and recorded an expense of $634,407.
	In March, 2012 the Company authorized the issuance of 71,429 shares of its $.001 par value common stock with a restrictive legend pursuant to existing employment agreements and recorded an expense of $181,874.
	In May, 2012, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $2.765 per share expiring in May, 2016.  These warrants were valued at $47,400 and recorded as consulting expense.
	In June , 2012, the Company’s Board of Directors authorized the issuance of 2,858 shares of its Series A Preferred stock with a restrictive legend pursuant to a Consulting Agreement and recorded a recorded an expense of $ 3,287.
	In June, 2012 the Company authorized the issuance of 300,000 shares of its Series A Preferred stock $.001 par value with a restrictive legend as additional stock based compensation for successful prosecution of the Company’s Patent applications and recorded an expense of $345,172.
	For the year ended June 30, 2012, the Company’s Board of Directors authorized the issuance of 26,624 shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $72,000.
	Fiscal Year Ending June 30, 2013 Transactions
	In August, 2012, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $2.38 per share expiring in August 2016.  These warrants were valued at $40,800 and recorded as consulting expense.
	In November 2012, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $1.995 per share expiring in November 2016.  These warrants were valued at $34,200 and recorded as consulting expense.
	On February 1, 2013, the Registrant consummated an offering (the “Offering”) in the aggregate amount of $6,000,000 for its Unsecured 8% Coupon Series B Convertible Debenture (the “Debentures”) to four equity investors comprised of private, family investment offices and a charitable foundation.
	On February 1, 2013, the Company authorized the issuance of 571,429 shares of its $.001 par value common stock with a restrictive legend for the payment of additional interest payable to the holders of the Company’s Series B Convertible Debentures and recognized a charge for interest expense of $665,497.
	In February 2013, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of common stock at $1.855 per share expiring in February 2017.  These warrants were valued at $31,800 and recorded as consulting expense.
	In March, 2013, the Company authorized the issuance of 71,429 shares of its $.001 par value common stock with a restrictive legend pursuant to existing employment agreements and recorded an expense of $60,000.
	In March, 2013, the Company authorized the issuance of 169,643 shares of its Series A Preferred stock $.001 par value with a restrictive legend pursuant to existing employment agreements and recorded an expense of $445,044.
	For the year ended June 30, 2013, the Company’s Board of Directors authorized the issuance of 42,979 shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $84,960.
	For the year ended June 30, 2013, the Company’s Board of Directors authorized the issuance of 8,520 shares of its common stock with a restrictive legend for Director services. The Company recorded an expense of $18,750.
	Fiscal Year Ending June 30, 2014 Transactions
	In accordance with the Company’s reverse stock split on a 1 for 3.5 basis, effective September 10, 2013, the Company filed a Certificate of Change to its Articles of Incorporation pursuant to Section 78.209 of the Nevada Revised Statutes (the “Amendment”) on September 3, 2013. The Amendment effectuated a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) by simultaneously decreasing the number of the Company’s authorized and outstanding capital stock on a basis of 1 for 3.5 shares (the “Split”). Accordingly, upon effectiveness of the Split, the Company’s authorized capital stock shall consist of (i) 85,714,286 shares of Common Stock and (ii) 5,714,286 blank check preferred shares, par value $0.001 (the “Preferred Stock”), of which approximately 50,028,701 shares of Common Stock and 2,990,000 shares of Preferred Stock were outstanding. All share amounts and per share amounts have been restated to reflect this reverse stock split. In conjunction with the reverse stock split, the Company’s Board of Directors authorized the issuance of 5,940 shares of the Company’s common stock to round up fractional shares resulting from the reverse stock split.
	The Company elected to effectuate the Reverse Split in order that the price of the Common Stock qualify for listing on a national securities exchange. The Amendment was unanimously approved by the Board of Directors so that the Common Stock would comply with such listing requirement
	On September 9, 2013, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $3.50 (“Purchase Price”) per Unit, consisting of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $5.25 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”) The Warrants are exercisable immediately and expire five years after issuance.
	On September 12, 2013, post reverse -split the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”), and the Company raised gross proceeds of $10,308,996 before estimated expenses of the Offering of approximately $618,540, which includes placement agent and attorneys’ fees. The Company issued 2,945,428 Units. On September 25, 2013 certain of these Unit Holders exercised 35,357 Warrants to purchase 35,357 shares of the Company’s common stock, par value $0.001 per share, for gross proceeds of $185,624. On January 21, 2014 and February 6, 2014 certain of these Unit Holders exercised 75,000 and 25,000 Warrants to respectively purchase 75,000 and 25,000 shares of the Company’s common stock, par value $0.001 per share, for gross proceeds of $393,750 and $131,750 respectively.
	The Company estimated the relative fair value of the warrants on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
			September  9, 2013
	Expected life (year)		5
	Expected volatility		78.39	%
	Expected annual rate of quarterly dividends		0	%
	Risk-free rate(s)		1.39	%
	The estimated relative fair value of the warrants issued in conjunction with the aforesaid offering was $5,684,380 at the date of issuance using the Black-Scholes Option Pricing Model.
	The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-184626), which was declared effective by the Securities and Exchange Commission on December 21, 2012. The Company, pursuant to Rule 424(b) under the Securities Act of 1933, has filed with the Securities and Exchange Commission a prospectus supplement relating to the Offering.
	In connection with the Offering, pursuant to a Placement Agency Agreement dated September 9, 2013 among Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”), the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the “Compensation Warrants”) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share. The Compensation Warrants will otherwise comply with FINRA Rule 5110(g)(1) in that for a period of nine months after the issuance date of the Compensation Warrants, neither the Compensation Warrants nor any warrant shares issued upon exercise of the compensation warrants shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Closing. Upon issuance of the commission warrants , the company recognized Costs associated with the sale of securities ( a capital item ) of $113,696 and a corresponding increase in additional paid in capital of $113,696.
	On September 25, 2013, the Company’s Common Stock began trading on the NYSE MKT exchange under the symbol NNVC.
	On January 21, 2014, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $5.25 (“Purchase Price”) per Unit. The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Company’s stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Company’s stock on Friday, January 17, 2014.  Each Unit consisted of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (“Warrant”), issuable upon exercise of the Warrant at the exercise price of $6.05 per share (the “Warrant Shares”, collectively with the Units, Common Stock and Warrant, the “Securities”). The Warrants are exercisable immediately and expire five years after issuance.
	On January 24, 2014, the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”) of 3,815,285 shares of Common Stock and 2,479,935 Warrants, and the Company raised gross proceeds of $20,030,206 before estimated expenses of the Offering of approximately $1,200,000, which includes placement agent fees but does not include and attorneys’ fees and other expenses. The Company intends to use the proceeds for general business purposes and expects that it will be able to accelerate the development of its drug candidate pipeline with this additional funding.
	The Company estimated the relative fair value of the warrants on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
			January 24, 2014
	Expected life (year)		5
	Expected volatility		78.39	%
	Expected annual rate of quarterly dividends		0	%
	Risk-free rate(s)		0.37	%
	The estimated relative fair value of the warrants issued in conjunction with the aforesaid offering was $7,762,196 at the date of issuance using the Black-Scholes Option Pricing Model.
	The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-184626), which was declared effective by the Securities and Exchange Commission on December 21, 2012 and Form S-3MEF (File No. 333-193439).
	In connection with the Offering, pursuant to a Placement Agency Agreement dated January 20, 2014 among Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”), the Company paid the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the “Compensation Warrants”) representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share. The Compensation Warrants will otherwise comply with FINRA Rule 5110(g)(1) in that for a period of six months after the issuance date of the Compensation Warrants, neither the Compensation Warrants nor any warrant shares issued upon exercise of the compensation warrants shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Closing.
	Unregistered Securities
	In August, 2013, the Scientific Advisory Board (SAB) was granted warrants to purchase 21,000 shares of Common Stock at $5.17 per share expiring in August, 2017.  These warrants were valued at $106,050 and recorded as consulting expense.
	In September, 2013, the Company’s Board of Directors authorized the issuance of Warrants to Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”) to purchase a total of 58,910 shares of Common Stock at $5.25 per share expiring in September, 2018.  These warrants were valued at $113,696 and recorded as Placement Agents Fees related to the sale of Common Shares and Warrants on September 10, 2013.
	For the three months ended September 30, 2013, the Company’s Board of Directors authorized the issuance of 10,311 shares of Common Stock with a restrictive legend for consulting services. The Company recorded an expense of $21,000.
	For the three months ended September 30, 2013, the Company’s Board of Directors authorized the issuance of 5,501 shares of Common Stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.
	In October, 2013, the Board of Directors authorized the issuance of 5,025 shares of the Company’s Series A Preferred Stock, $0.001 par value as, employee compensation and recognized an expense of $35,995.
	In November, 2013, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,143 shares of Common Stock at $6.56 per share expiring in November, 2017.  These warrants were valued at $31,552 and recorded as consulting expense.
In December, 2013, the Company issued 7,143 shares of Common Stock with a restrictive legend at $3.50 per share upon the exercise of Warrants.
For the three months ended December 31, 2013, the Company’s Board of Directors authorized the issuance of 4,069 shares of its Common Stock with a restrictive legend for consulting services. The Company recorded an expense of $21,000.
In February, 2014, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,148 shares of Common Stock at $3.32 per share expiring in February, 2018.  These warrants were valued at $30,352 and recorded as consulting expense
For the three months ended March 31, 2014, the Company’s Board of Directors authorized the issuance of 2,247 shares of Common Stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.
For the three months ended March 31, 2014, the Company’s Board of Directors authorized the issuance of 4,988 shares of common stock with a restrictive legend for consulting services. The Company recorded an expense of $21,000.
For the three months ended March 31, 2014, the Board of Directors authorized the issuance of 20,695 shares of the Company’s Series A Preferred Stock, $0.001 par value, as employee compensation and recognized an expense of $192,041.
In May, 2014, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,148 shares of Common Stock at $3.16 per share expiring in May, 2018.  These warrants were valued at $31,895 and recorded as consulting expense.
For the three months ended June 30, 2014 the Company’s Board of Directors authorized the issuance of 3,178 shares of Common Stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.
For the three months ended June 30, 2014, the Company’s Board of Directors authorized the issuance of 10,304 shares of common stock with a restrictive legend for consulting services. The Company recorded an expense of $39,000.
For the three months ended June 30, 2014, the Board of Directors authorized the issuance of 177,359 shares of the Company’s Series A Preferred Stock, $0.001 par value, as employee compensation and recognized an expense of $1,894,975.
In June, 2014, the Company authorized the issuance of 71,429 shares of its $.001 par value common stock with a restrictive legend pursuant to existing employment agreements and recorded an expense of $297,860.
The Company estimated the relative fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		June 30, 2014
Expected life (year)			4
Expected volatility			78.39%- 98.09%
Expected annual rate of quarterly dividends			0.00%
Risk-free rate(s)			.37-1.12%
The estimated relative fair value of the warrants issued to the Scientific Advisory Board as a whole for the fiscal year ended June 30, 2014 was $199,849 at the date of issuance using the Black-Scholes Option Pricing Model.
There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a change of control of the Company. The Company, therefore, estimated the relative fair value of the Preferred A shares granted to various Employees on the date of grant The Preferred Series A shares fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered either by the Company or a Change of Control. The valuations of the Series A Prefered Stock as of 6/30/14 used the following inputs:
	a.	The common stock price (post-reverse split) was in the range $2.45 to $3.90;
	b.	47,026,173 to 54,614,930 shares outstanding and Series A Preferred shares with 2,572 (post–split 9/10/13) issued monthly ; and 169,644 issued annually to employees .
	c.	A 5.36% premium over the common shares for the voting preferences;
	d.	54,506,459 to 62,208,499 total voting shares and the monthly shares representing voting rights of 0.042% to 0.484% of the total; and the annual shares representing 1.02% to 2.389% of the total;
	e.	The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 anda restricted term of 3.67 to 2.67 years;
	f.	42.87% to 27.11% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 121.97% to 265.70% volatility, 0.37% to 1.62% riskfree rate) applied to the converted common.
Based upon the above assumptions the estimated relative fair value of the preferred shares issued to company employees as a whole as a whole for the fiscal year ended June 30, 2014 was calculated to be $2,123,011. There are no assurances that such estimated fair value represents a market value between a willing buyer and seller

Stock_Options_and_Warrants

Stock Options and Warrants	12 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 9 - Stock Options and Warrants
	Stock Options
	The following table presents the combined activity of stock options issued for the years ended June 30, as follows:
	Stock Options	Number of	Weighted		Weighted	Aggregate
		Shares	Average		Average	Intrinsic
			Exercise Price		Remaining	Value at
			per share ($)		Contractual	Issuance ($)
					Term (years)
	Outstanding at June 30, 2011	535,715		0.35	4.24		439,286
	Granted	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2012	535,715		0.35	3.23		439,286
	Granted	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2013	535,715		0.35	2.23		1,521,429
	Granted	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2014	535,715		0.35	1.23		2,094,643
	As of June 30, 2014 there was no unrecognized compensation cost.
	Stock Warrants
	Stock Warrants	Number of Shares	Weighted		Weighted	Aggregate
			Average		Average	Intrinsic Value
			Exercise Price		Remaining	($)
			per share ($)		Contractual Term
					(years)
	Outstanding at June 30, 2011	3,263,415		4.095	0.95		-
	Granted	68,572		3.71	2.5		-
	Exercised			-	-		-
	Expired			-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2012	3,331,987		4.06	1.69		-
	Granted	68,572		2.17	3.51		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2013	3,400,559		4.025	0.86		134,559
	Granted	5,629,152		5.63	4.37		-
	Exercised	142,500		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
							-
	Outstanding at June 30, 2014	8,887,211		5.01	2.78		2,278,458
	Of the above warrants, ;  3,263,414 expire in fiscal year ending June 30, 2015; and 68,572 expire in fiscal year ended June 30, 2016; 68,571 expire in fiscal year ending June 30, 2017; 127,487 in fiscal year ending June 30,2018; 5,359,169 in fiscal year ending June 30, 2019.

Income_Tax_Provision

Income Tax Provision	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 10 - Income Tax Provision
	Deferred Tax Assets
	Deferred tax assets arise from the temporary differences between financial statements and income tax recognition of net operating losses. The current net operating loss carry-forwards will begin to expire in the year 2034 if not utilized. Utilization of the Company’s net operating loss carry-forwards are limited based on changes in ownership as defined in Internal Revenue Code Section 382. As of June 30, 2014 the Company accumulated a tax loss of $33,238,766, resulting in a deferred tax benefit of approximately $20,172,664, which has been offset by a full valuation allowance.
	The following is reconciliation of income tax expense (benefit):
		June 30, 2014		June 30, 2013		June 30, 2012
	Net operating loss carry-forwards	$	11,104,134	$	6,845,928	$	4,283,519
	Research and development credit		6,851,851		5,390,274		2,764,875
	Other		2,216,680		1,796,031		1,701,915
	Gross deferred tax assets		20,172,664		14,032,233		8,750,309
	Valuation allowances		-20,172,664		-14,032,233		-8,750,309
	Deferred tax assets, net	$	-	$	-	$	-
	During the fiscal year ended June 30, 2014, 2013 and 2012, the valuation allowance increased by $6,140,431, $5,281,924, and $2,206,785, respectively.
	During the fiscal years ended on June 30, 2014, 2013, and 2012 the Company recognized no refundable Research and Development tax credit.

Credit_risk

Credit risk	12 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Credit Risk [Text Block]	'
	Note 11 – Credit Risk
	Credit Risk
	Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents.  As of June 30, 2014, substantially all of the Company’s cash and cash equivalents were held by major financial institutions and the balance at certain accounts exceeded the maximum amount insured by the Federal Deposits Insurance Corporation (“FDIC”).  However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 12 - Commitments and Contingencies
	Operating Lease
	The Company’s principal executive offices are located at 135 Wood Street, West Haven, Connecticut, and include approximately 7,000 square feet of office and laboratory space at a base monthly rent of $8,695. The term of lease expired in February 28, 2011, and is now on a month-by-month basis.
	Total rent expense amounted to $104,340, $102,030 and $110,633 for the fiscal year ended June 30, 2014, 2013 and 2012, respectively.
	Litigation
	From time to time, we may be a party to legal proceedings in the ordinary course of our business in addition to those described below. We do not, however, expect such other legal proceedings to have a material adverse effect on our business, financial condition or results of operations. We record an accrual for legal contingencies when we determine that it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. In making such determinations we evaluate, among other things, the degree of probability of an unfavorable outcome and, when it is probable that a liability has been incurred, our ability to make a reasonable estimate of the loss. We review these accruals each reporting period and make revisions based on changes in facts and circumstances.
	On or around January 18, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-654437-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”).  The Complaint seeks to compel inspection of the Company’s books and records.  On or about February 14, 2012 we filed a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted.  The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which it is not entitled.  The Complaint by a holder of less than 1 percent of the common stock of the Company seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute.  Management believes that this lawsuit has no merit or basis and intends to vigorously defend it.  Monetary damages have not been claimed and as a result no accrual has been made in relation to this litigation. On April 9, 2012, the Court dismissed the Complaint for failure to state a Claim for which relief could be granted.
	On or about April 13, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-659535-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”). The Complaint seeks to compel inspection of the Company’s books and records. On or about May 2, 2012, the Company filed a Demand for Security of Costs. Upon filing of the Demand, proceedings relative to the Company are stayed pending posting of the demanded security (or plaintiff engages in motion practice about the Demand). The Company may seek dismissal of the complaint if plaintiff has not posted the demanded security (or engaged the court). The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which the Company believes it is not entitled. The Complaint, by a holder of less than 1 percent of the common stock of the Company, seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute. On or about July 18, 2012, the Plaintiff moved to amend its answer. On or about August 8, 2012, we filed our opposition to Plaintiff’s Motion to Amend and a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted. On or about September 13, 2012 the court granted the Plaintiff’s Motion to Amend. On or about September 17, 2012 the Plaintiff served its “Second Amended Shareholder Derivative Complaint” upon our Counsel in Nevada. As in the prior two complaints that this Plaintiff has filed in this action, the Second Amended Complaint sought to compel inspection of the Company’s books and records, sought injunctive relief, an accounting and alleges breach of Fiduciary by Dr. Seymour and Dr. Diwan. On or about October 11, 2012, we filed a Motion to Dismiss the Second Amended Complaint for failure to state a claim upon which relief can be granted. On or about December 4, 2012, the Court granted the Company’s Motion to Dismiss with respect to Dr. Seymour and Dr. Diwan and ordered the case dismissed as to all claims but the Plaintiff’s request to compel documents required to be maintained by the Company’s registered agent in Nevada pursuant to NRS 78.105. On or about December 26, 2012, the Company provided the Plaintiff with each of the documents to which it is entitled. Management believes that the Plaintiff does not have a legal or good faith basis for inspection or copying of its shareholder’s list and intends to vigorously defend the production thereof. In May, 2013, the Plaintiff filed a motion for permission to file a third amended complaint. The Company subsequently filed a motion to dismiss and for Summary Judgment. The Court denied the Motion to Dismiss and for Summary Judgment and ordered the Plaintiff to file its Third Amended Complaint. On or about July 15, 2013 the Company Petitioned the Nevada Supreme Court for a Writ of Prohibition or Mandamus reversing the trial Court’s denial of Summary Judgment. Thereafter, on or about September 20, 2013, the Nevada Supreme Court denied the Company’s Writ Petition. The Company filed its answer to the Third Amended Complaint, which contains only one cause of action which is identical to the sole cause of action which was not dismissed from the Second Amended Complaint. Specifically, the Third Amended Complaint seeks only to compel production of books and records required to be maintained by the Company’s Registered Agent pursuant to NRS 78.105 Management believes that the Company’s registered Agent has provided the Plaintiff with all documents to which it is entitled pursuant to NRS 78.105 and that this lawsuit has no merit or basis. The Company has vigorously defended this lawsuit. Specific monetary damages have not been claimed and as a result no accrual has been made in relation to this litigation In June, 2014 the parties agreed to mediation of the matters in dispute. The parties to this litigation have determined that it is not in the interest of either party to continue this litigation and had agreed to a settlement of this dispute, subject to dismissal with prejudice of a substantially identical lawsuit initiated by the same plaintiff in The United States District Court for the District of Colorado. On September 11, 2014 a judgement of dismissal was entered by the court in Colorado. Pursuant to the Settlement Agreement, the Settlement Agreement and a proposed Order of Dismissal with Prejudice were submitted to the Nevada District Court for review and dismissal with prejudice. On September 17, 2014 the Nevada District Court dismissed the case with prejudice Upon dismissal of this matter in Nevada, the Company has agreed to reimburse the Plaintiff for $150,000 of its legal fees.
	On or about July 15, 2013 the same Plaintiff that had filed the repetitive complaints in the Nevada action as set forth in the preceding paragraph (Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc.)filed a Shareholder Derivative complaint with the United States District Court for the District of Colorado.  The Plaintiff asserts the action is a shareholder derivative action and the Company is solely a nominal defendant.  The Company maintains that it, as well as the individual defendants, Messrs. Seymour and Diwan, have not been served in the action. However, a default had been filed against the Company, which has been vacated. The Complaint alleges that the Company has failed to deliver information requested by the Plaintiff, the identical information the Plaintiff is seeking inspection of in the Nevada action, and that the individual defendants, Messrs. Seymour and Diwan, breached their fiduciary duties to the Company and caused it financial harm.  The Plaintiff demands an order to inspect the Company’s records, an order revoking Messrs. Diwan and Seymour from the Board of Directors, equitable relief, and consequential and punitive damages.  The Company believes these claims have no merit and the Company intends to defend this action vigorously. The Company has moved the District Court to dismiss the action in its entirety. Though consequential and punitive damages are claimed, no facts have been submitted to support such claim. Management has determined that such claims are specious and not relevant to the Company and no accrual has been made in relation to this litigation. On September 11, 2014 an order dismissing the action with prejudice was entered by the court
	There are no other legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.
	Officers’ Compensation
	On March 3, 2010, the Company entered into employment agreements with its two executive officers, Eugene Seymour, Chief Executive Officer and Chief Financial Officer and Anil Diwan, President and Chairman of Board.  Both agreements provided a minimum annual base salary of $250,000 for a term of four (4) years. In addition, Dr. Seymour and Dr. Diwan are eligible for an increase in base salary to $275,000 if the Company consummates a financing with gross proceeds of at least $5,000,000.  Also, the base salary shall increase to $300,000 for Dr. Seymour and $300,000 for Dr. Diwan if the Company becomes listed on a national stock exchange.
	As additional compensation under the employment agreements, the Company issued 71,429 shares of the Company’s Series A Preferred Stock and issued an additional 71,429 shares of Series A Preferred Stock on each anniversary of the respective employment agreements. The Compensation Committee of the Board of Directors extended the current provisions of these Employment Agreements pending its review of the current industry compensation arrangements and Employment agreements
	On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development.  The employment agreement provides for term of four years with a base salary of $150,000.  In addition, the Company issued 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock, and issued an additional 26,786 shares of Series A Preferred Stock and 35,715 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements
	On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer.  The employment agreement provided for a term of four years with a base salary of $150,000.  In addition, the Company issued 35,715 shares of common stock, and issued an additional 35,715 shares of common stock on each anniversary date of the agreement. The Compensation Committee of the Board of Directors extended the current provisions of the Employment Agreement pending its review of current industry compensation arrangements and Employment agreements
	On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Interim Chief Financial Officer.  The employment agreement provides for a base salary of $9,000 per month and 2,572 shares of Series A Preferred Stock, also on a monthly basis.
	License Agreements
	The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4).  If it loses the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates.

Subsequent_Events

Subsequent Events	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 13 - Subsequent Events
	Management performed an evaluation of the Company’s activity through the date these financials were issued to determine if they must be reported. The Management of the Company determined that there were certain reportable subsequent events to be disclosed as follows:
		1	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenturehad been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 shall be calculated on a per diem basis from the Closing Date.
	The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the “Redemption Payment”) in cash or, at the option of the Holder, a number of shares of the Company’s Common Stock. If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the “Redemption Date”), the Company must redeem the Debenture by delivering to the Holder 951,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, and additional interest of 7% per annum for the period from the Closing Date to the Redemption Date.
	As additional interest on the Debenture, the Company shall issue 187,000 shares of its restricted Series A Preferred Stock (the “Series A”) to the Holder. Each shares of Series A votes at 9 votes per share. In addition, only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects.
	The Offering was conducted directly by the Company without the use of a placement agent. Accordingly, no placement agent fees or other commissions were paid by the Company in connection with the Offering.
		2	On September 5, 2014, NanoViricides, Inc. (the “Company”) accepted notices to exercise warrants for the purchase of an aggregate of 2,136,655 shares of the Company’s common stock at the exercise price of $3.50 per share for aggregate proceeds of $7,478,292.50. On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009, as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. As of August 15, 2014, any Registered Warrants as specified above and not previously exercised have expired.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Fiscal Period, Policy [Policy Text Block]	'
	Fiscal Year End
	The Company elected June 30th as its fiscal year end date upon its formation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	The Company’s significant estimates include the fair value of financial instruments; the carrying value, recoverability and impairment of long-lived assets, including the values assigned to and estimated useful lives of property and equipment and trade mark, and underlying assumptions to estimate the fair value of derivative financial instruments; income tax rate, income tax provision and valuation allowance of deferred tax assets. These significant accounting estimates bear the risk of change due to the fact that there are uncertainties attached to those estimates and certain estimates are difficult to measure or value.
	Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
	Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, if deemed appropriate, those estimates are adjusted accordingly.
	Actual results could differ from those estimates.
Reclassification, Policy [Policy Text Block]	'
	Reclassification
	Certain reclassifications have been made in prior year’s financial statements to conform to the financial presentation used in the current year. These reclassifications from General and Administrative Expenses to Research and Development expenses had no effect on total operating expenses, operating loss or net loss for any period presented.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Derivatives and Fair Value of Financial Instruments
	The Company applied paragraph 815-10-05-4 of the FASB Accounting Standards Codification to the Series B Convertible Debenture issued January 15, 2013.  Based on the guidance in paragraph 815-10-05-4 of the FASB Accounting Standards Codification the Company concluded these instruments were required to be accounted for as derivatives as of January 15, 2013.  The Company records the fair value of the preferred stock that are classified as derivatives on its balance sheet at fair value with changes in the values of these derivatives reflected in the consolidated statements of operations as “Gain (loss) on derivative liabilities.”  These derivative instruments are not designated as hedging instruments under paragraph 815-10-05-4 of the FASB Accounting Standards Codification and are disclosed on the balance sheet under Derivative Liabilities.
	The Company follows paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments and paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:
		Level  1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
		Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
		Level 3	Pricing inputs that are generally observable inputs and not corroborated by market data.
	Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
	The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepayments and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.
	The Company’s Level 3 financial liabilities consist of the Series B convertible debenture issued January 15, 2013 for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. We have valued the automatic conditional conversion, re-pricing/down-round, change of control; default and follow-on offering provisions using a lattice model, with the assistance of a valuation consultant, for which management understands the methodologies. These models incorporate transaction details such as Company stock price, contractual terms, maturity, risk free rates, as well as assumptions about future financings, volatility, and holder behavior as of issuance and June 30, 2014. The primary assumptions include: projected annual volatility of 92%-95%; the follow-on securities purchase option; the conversion feature as a percentage of Market; automatic/conditional conversions; market price trigger events.
	As of June 30, 2014, the Company’s derivative financial instruments are embedded derivatives associated with certain of the Company’s unsecured convertible debentures. The Company’s Series B convertible debenture issued to five (5) unrelated investors is a hybrid instrument, which warrants separate accounting as a derivative instrument. The embedded derivative feature has been bifurcated from the debt host contract, referred to as the Derivative Liability”, which resulted in a reduction of the initial carrying amount (as unamortized discount) of the Debentures. The unamortized discount is amortized to interest expense using the effective interest method over the life of the Debentures. The embedded derivative feature includes the conversion feature within the notes and an early redemption option.  The compound embedded derivatives within the convertible Debentures have been recorded at fair value at the date of issuance; and are marked-to-market each reporting period with changes in fair value recorded to the Company’s statement of operations as Change in fair value of derivative liabilities.
	The Series B Convertible Debenture were valued at 6/30/14. The following assumptions were used for the valuation of the embedded derivative:
		-	The balance of the Series B Convertible Debenture as of 6/30/14 is $6,000,000 following the interest payment on 6/30/14;
		-	The underlying stock price was used as the fair value of the common stock;
		-	The stock price increased from $0.9143 to $1.2086 which significantly increased the warrant value with the $1.00 exercise price (from out to in the money);
		-	The projected annual volatility was based on the Company historical volatility:
	3/31/14		95	%
	6/30/14		92	%
		-	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;
		-	The company would redeem the debentures projected initially at 0% of the time and increase monthly by 1.0% to a maximum of 20.0% (from alternative financing being available for a Redemption event to occur);
		-	The Holder would automatically convert the interest if the company was not in default;
		-	The Holder would automatically convert the debenture at maturity if the registration was effective and the company was not in default.
	Derivative Valuation – Additional Redemption and Interest Warrants
	The Redemption and Interest Warrants potentially issued were valued as of 6/30/14 (for all scenarios based on the lattice projected stock prices and historical volatility of the company) and the following assumptions were used for the valuation of the derivative:
		-	The stock price would fluctuate with the Company projected volatility;
		-	The projected volatility curve for each valuation period was based on the historical volatility of the Company (see previous section);
		-	The Holder would exercise the warrant at maturity if the stock price was above the exercise price;
		-	The Holder would exercise the warrant at target prices starting at the greater of 2 times the exercise price or the stock price; and lowering such target as the warrants approached maturity.
		-	In this period no warrants were issued or exercised.
	Based on these management assumptions, the fair value of the Redemption and Interest Warrants (“Additional Warrants” or “Warrants”) derivative liability as of the projected issuance dates. Redemption Warrants assumed issuance as of the valuation dates and the Interest Warrants scenario valuations assume issuance 1/15/15.
	Series B Convertible Debenture		6,000,000		6,000,000
	Derivative Value		3,824,987		5,699,703
	Mark to Market		-3,752,933		1,874,716
	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the fiscal year ended June 30, 2014:
			Fair Value Measurements
			Using Level 3 Inputs
				Derivative
				Liabilities			Totals
	Balance, June 30, 2011			17,519			17,519
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss			-172,245			-172,245
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements			1,233,424			1,233,424
	Transfers in and/or out of Level 3
	Balance, June 30, 2012			1,078,698			1,078,698
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss			-1,249,335			-1,249,335
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements			3,922,282			3,922,282
	Transfers in and/or out of Level 3			-			-
	Balance, June 30, 2013		$	3,751,645		$	3,751,645
	Included in Net (Income) Loss			1,948,058			1,948,058
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements			-			-
	Transfers in and/or out of Level 3			-			-
	Balance, June 30, 2014		$	5,699,703		$	5,699,703
	The fair value of the derivatives was $2,735,310 as of January 15, 2013 upon issuance and was $5,699,703 at June 30, 2014.
	The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring.  Accordingly, changes to these assessments could materially affect the valuation.
	Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’'s-length transactions unless such representations can be substantiated.
Carrying Value Recoverability And Impairment Of Long Lived Assets [Policy Text Block]	'
	Carrying Value, Recoverability and Impairment of Long-Lived Assets
	The Company has adopted paragraph 360-10-35-17 of the FASB Accounting Standards Codification for its long-lived assets. The Company’s long-lived assets, which include property and equipment and trade mark and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.
	The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates acquired assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events.
	The impairment charges, if any, is included in operating expenses in the statements of operations.
	The Company determined that there were no impairments of long-lived assets as of June 30, 2014 or 2013.
Fari Value of Financial Assets and Liability on Recurring Basis [Policy Text Block]	'
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Level 3 Financial Liabilities – Derivative Warrant Liabilities
	The Company uses Level 3 of the fair value hierarchy to measure the fair value of the derivative liabilities and revalues its derivative warrant liability at every reporting period and recognizes gains or losses in the statements of operations that are attributable to the change in the fair value of the derivative warrant liability.
	Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative Liabilities:
			As of June 30, 2014
			Carrying		Fair Value Measurements Using
			Value		Level 1		Level 2	Level 3	Total
	Liabilities
	Derivative Liabilities associated with
	Series B Convertible Debentures		5,699,703					5,699,703	5,699,703
	Total Derivative Liabilities		5,699,703					5,699,703	5,699,703
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets (generally five (5) to seven (7) years), or lease term for leasehold improvement, using the straight-line method. Expenditures for major additions and betterments are capitalized.  Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
Intangible Assets Other Than Goodwill [Policy Text Block]	'
	Intangible Assets Other Than Goodwill
	The Company has adopted Subtopic 350-30 of the FASB Accounting Standards Codification for intangible assets other than goodwill. Under the requirements, the Company amortizes the acquisition costs of intangible assets other than goodwill on a straight-line basis over or their estimated useful lives, the terms of the exclusive licenses and/or agreements, or the terms of legal lives of the patents, whichever is shorter. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation for Obtaining Employee Services
	The Company accounts for its stock based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of section 718-10-30 of the FASB Accounting Standards Codification. Pursuant to paragraph 718-10-30-6 of the FASB Accounting Standards Codification, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
	The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.  The ranges of assumptions for inputs are as follows:
	⋅	Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. Pursuant to paragraph 718-50-S99-1, it may be appropriate to use the simplified method, if (i) A company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) A company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) A company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as the company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.
	⋅	Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
	⋅	Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments.
	⋅	Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments.
	The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award.
Equity Instruments Issued To Parties Other Than Employees For Acquiring Goods Or Services [Policy Text Block]	'
	Equity Instruments Issued to Parties other than Employees for Acquiring Goods or Services
	The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of section 505-50-30 of the FASB Accounting Standards Codification (“FASB ASC Section 505-50-30”).
	Pursuant to FASB ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
	The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows:
	⋅	Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments.  If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
	⋅	Expected volatility of the entity’s shares and the method used to estimate it.  Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index.  The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility.  If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
	⋅	Expected annual rate of quarterly dividends.  An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends.  The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments.
	⋅	Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments.
	Pursuant to ASC paragraph 505-50-25-7, if fully vested, non-forfeitable equity instruments are issued at the date the grantor and grantee enter into an agreement for goods or services (no specific performance is required by the grantee to retain those equity instruments), then, because of the elimination of any obligation on the part of the counterparty to earn the equity instruments, a measurement date has been reached. A grantor shall recognize the equity instruments when they are issued (in most cases, when the agreement is entered into). Whether the corresponding cost is an immediate expense or a prepaid asset (or whether the debit should be characterized as contra-equity under the requirements of paragraph 505-50-45-1) depends on the specific facts and circumstances. Pursuant to ASC paragraph 505-50-45-1, a grantor may conclude that an asset (other than a note or a receivable) has been received in return for fully vested, non-forfeitable equity instruments that are issued at the date the grantor and grantee enter into an agreement for goods or services (and no specific performance is required by the grantee in order to retain those equity instruments). Such an asset shall not be displayed as contra-equity by the grantor of the equity instruments. The transferability (or lack thereof) of the equity instruments shall not affect the balance sheet display of the asset. This guidance is limited to transactions in which equity instruments are transferred to other than employees in exchange for goods or services. Section 505-50-30 provides guidance on the determination of the measurement date for transactions that are within the scope of this Subtopic.
	Pursuant to ASC paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a stock option that the counterparty has the right to exercise expires unexercised.
	Pursuant to ASC paragraph 505-50-30-S99-1, if the Company receives a right to receive future services in exchange for unvested, forfeitable equity instruments, those equity instruments are treated as unissued for accounting purposes until the future services are received (that is, the instruments are not considered issued until they vest). Consequently, there would be no recognition at the measurement date and no entry should be recorded.
Related Parties [Policy Text Block]	'
	Related Parties
	The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.
	Pursuant to Section 850-10-20 the related parties include a. affiliates of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
	The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved b.  description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Commitments and Contingencies, Policy [Policy Text Block]	'
	Commitment and Contingencies
	The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
	Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
Income Tax, Policy [Policy Text Block]	'
	Income Tax Provision
	The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.  Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income and Comprehensive Income in the period that includes the enactment date.
	The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements.  Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty (50) percent likelihood of being realized upon ultimate settlement.  Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.  The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.
Income Tax Uncertainties, Policy [Policy Text Block]	'
	Uncertain Tax Positions
	The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the fiscal year ended June 30, 2014, 2012, or 2011.
	The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary.
	Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentrations of Risk
	Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
			Potentially Outstanding Dilutive Common Shares
			For the Fiscal		For the Fiscal		For the Fiscal
			Year		Year		Year
			Ended		Ended		Ended
			June 30, 2014		June 30, 2013		June 30, 2012
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.10 per share expiring ten (10) years from the date of issuance		535,714		535,714		535,714
	Sub-total: stock options		535,714		535,714		535,714
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28,2014		520,286		520,286		520,286
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28,2014		466,486		466,486		466,486
	Warrants issued from June 15, 2008 through May 15,2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28,2014		211,429		211,429		211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		561,628		568,771		568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014		1,437,871		1,437,871		1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015		65,714		65,714		65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016		68,571		68,571
	Warrants issued from August 16, 2013 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017		68,571		68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through March 31, 2014		2,802,928
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017		17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018		58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017		17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019		2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019		76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018		17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018		17148
	Sub-total: warrants		8,887,212		3,407,699		3,270,557
	Total potentially outstanding dilutive common shares		9,422,926		3,943,413		3,806,271
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At June 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,408,451 based upon the Selling price of the Company’s common stock on June 30, 2014 of $4.26. At June 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,142,858.
	The Company has also issued 3,193,079 of $0.001 par value Convertible Preferred A shares to investors and others. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At June 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 11,175,776.
Cash Flows Reporting [Policy Text Block]	'
	Cash Flows Reporting
	The Company adopted paragraph 230-10-45-24 of the FASB Accounting Standards Codification for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB Accounting Standards Codification to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.  The Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB Accounting Standards Codification.
Subsequent Events, Policy [Policy Text Block]	'
	Subsequent Events
	The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements are issued.  Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update change the requirements for reporting discontinued operations in Subtopic 205-20.
	Under the new guidance, a discontinued operation is defined as a disposal of a component or group of components that is disposed of or is classified as held for sale and “represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results.” The ASU states that a strategic shift could include a disposal of (i) a major geographical area of operations, (ii) a major line of business, (iii) a major equity method investment, or (iv) other major parts of an entity. Although “major” is not defined, the standard provides examples of when a disposal qualifies as a discontinued operation.
	The ASU also requires additional disclosures about discontinued operations that will provide more information about the assets, liabilities, income and expenses of discontinued operations. In addition, the ASU requires disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation in the financial statements.
	The ASU is effective for public business entities for annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In May 2014, the FASB issued the FASB Accounting Standards Update No. 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”).
	This guidance amends the existing FASB Accounting Standards Codification, creating a new Topic 606, Revenue from Contracts with Customer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
	To achieve that core principle, an entity should apply the following steps:
		1	Identify the contract(s) with the customer
		2	Identify the performance obligations in the contract
		3	Determine the transaction price
		4	Allocate the transaction price to the performance obligations in the contract
		5	Recognize revenue when (or as) the entity satisfies a performance obligations
	The ASU also provides guidance on disclosures that should be provided to enable financial statement users to understand the nature, amount, timing, and uncertainty of revenue recognition and cash flows arising from contracts with customers.  Qualitative and quantitative information is required about the following:
	Contracts with customers – including revenue and impairments recognized, disaggregation of revenue, and information about contract balances and performance obligations (including the transaction price allocated to the remaining performance obligations)
		1	Significant judgments and changes in judgments – determining the timing of satisfaction of performance obligations (over time or at a point in time), and determining the transaction price and amounts allocated to performance obligations
		2	Assets recognized from the costs to obtain or fulfill a contract.
	ASU 2014-09 is effective for periods beginning after December 15, 2016, including interim reporting periods within that reporting period for all public entities.  Early application is not permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage. The Company adopted this guidance from June 30, 2014.
	In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation—Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
	The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.  The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition.  The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015.  Earlier adoption is permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements— Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
	The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
	This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted. The amendments of the ASU would not have a material effect on the accompanying financial statements
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	'
	The projected annual volatility was based on the Company historical volatility:
	3/31/14	95	%
	6/30/14	92	%
Schedule of Interest Rate Derivatives [Table Text Block]	'
	Redemption Warrants assumed issuance as of the valuation dates and the Interest Warrants scenario valuations assume issuance 1/15/15.
	Series B Convertible Debenture	6,000,000		6,000,000
	Derivative Value	3,824,987		5,699,703
	Mark to Market	-3,752,933		1,874,716
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]	'
	The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the fiscal year ended June 30, 2014:
		Fair Value Measurements
		Using Level 3 Inputs
		Derivative
		Liabilities			Totals
	Balance, June 30, 2010	$	-		$	-
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss		-			-
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements		17,519			17,519
	Transfers in and/or out of Level 3
	Balance, June 30, 2011		17,519			17,519
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss		-172,245			-172,245
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements		1,233,424			1,233,424
	Transfers in and/or out of Level 3
	Balance, June 30, 2012		1,078,698			1,078,698
	Total Gains or Losses (realized/unrealized)
	Included in Net (Income) Loss		-1,249,335			-1,249,335
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements		3,922,282			3,922,282
	Transfers in and/or out of Level 3		-			-
	Balance, June 30, 2013	$	3,751,645		$	3,751,645
	Included in Net (Income) Loss		-1,948,058			-1,948,058
	Included in Other Comprehensive Income
	Purchases, Issuances and Settlements		3.896.116			3,896,116
	Transfers in and/or out of Level 3		-			-
	Balance, June 30, 2014	$	5,699,703		$	5,699,703
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative Liabilities:
		As of June 30, 2014
		Carrying		Fair Value Measurements Using
		Value		Level 1		Level 2	Level 3	Total
	Liabilities
	Derivative Liabilities associated with
	Series B Convertible Debentures	5,699,703					5,699,703	5,699,703
	Total Derivative Liabilities	5,699,703					5,699,703	5,699,703
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the Fiscal		For the Fiscal		For the Fiscal
		Year		Year		Year
		Ended		Ended		Ended
		June 30, 2014		June 30, 2013		June 30, 2012
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.10 per share expiring ten (10) years from the date of issuance	535,714		535,714		535,714
	Sub-total: stock options	535,714		535,714		535,714
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28,2014	520,286		520,286		520,286
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring February 28,2014	466,486		466,486		466,486
	Warrants issued from June 15, 2008 through May 15,2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28,2014	211,429		211,429		211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014	561,628		568,771		568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring February 28, 2014	1,437,871		1,437,871		1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714		65,714		65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571		68,571
	Warrants issued from August 16, 2013 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571		68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through March 31, 2014	2,802,928
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Sub-total: warrants	8,887,212		3,407,699		3,270,557
	Total potentially outstanding dilutive common shares	9,422,926		3,943,413		3,806,271

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Fixed Assets
		June 30, 2014		June 30, 2013
	During the reporting period, InnoHaven, LLC, acquired fixed assets on behalf of the Company from third party vendors behalf of the Company at 1 Controls Drive, Shelton, Ct	$	4,500,000		-
	During the reporting Period, Thera Cour Pharma, Inc acquired fixed assets on behalf of the Company from third party vendors	$	528,720		-
	Account Payable – Related Party
		June  30, 2014		June 30, 2013
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. . In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc on the reporting date was	$	758,676	$	710,567
	The Accounts payable were offset by contractual advances of	$	709,221		546,783
	Net Account Payable to related party	$	49,455	$	163,784
	Research and Development Costs Paid to Related Parties
		June 30, 2014		June 30, 2013
	Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. As of June 30, 2014, pursuant to its license agreement, the Company has paid a security advance of $709,221 to and held by TheraCour Pharma, Inc. which is reflected in Prepaid Expenses. No royalties are due TheraCour from the Company’s inception through June 30, 2014.	$	2,611,754	$	1,988,046
	Long-Term Debentures Payable – Directors
		June 30, 2014		June 30, 2013
	On February 1, 2013, the Company raised $4M from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal. The warrants are priced at $3.50 and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.	$	4,000,000	$	4,000,000
	Repayments from inception to date		-		-
	Remaining balance		4,000,000		4,000,000
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 shall be calculated on a per diem basis from the Closing Date.		5,000,000		5,000,000
	Repayments from inception to date		-		-
	Remaining balance		5,000,000		5,000,000
		$	9,000,000	$	9,000,000

Concentrations_Tables

Concentrations (Tables)	12 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
	Vendor purchase concentrations for December 31, 2014 and 2013 are as follows:
		Net Purchases								Accounts Payable
		For the years ended June 30								As of June 30,
		2014				2013				2014				2013
	TheraCour Pharma, Inc		3,140,474	36.2	%		1,988,046	30.2	%		758,676	75.6	%		710,567	72.97	%
	Kard Scientific, Inc.		314,156	3.6	%		1,035,983	15.7	%		123,570	10.9	%		123,132	12.64	%
	Total		3,454,630	39.9	%		3,024,029	45.9	%		882,246	77.7	%		833,699	85.6	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
		June 30, 2014		June 30, 2013
	GMP Facility	$	3,099,780	$	397,407
	Office Equipment		30,048		30,048
	Furniture and Fixtures		1,400		1,400
	Lab Equipment		3,605,514		1,076,793
	Total Property and Equipment		6,736,742		1,505,648
	Less Accumulated Depreciation		-1,239,986		-1,036,752
	Property and Equipment, Net	$	5,496,756	$	468,896

Trademark_and_Patents_Tables

Trademark and Patents (Tables)	12 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:
		June 30, 2014		June 30, 2013
	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-50,696		-41,921
	Trademarks and Patents, Net	$	408,258	$	417,033

Equity_Transactions_Tables

Equity Transactions (Tables)	12 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders Equity [Table Text Block]	'
	The Company estimated the relative fair value of the warrants on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		September  9, 2013
	Expected life (year)	5
	Expected volatility	78.39	%
	Expected annual rate of quarterly dividends	0	%
	Risk-free rate(s)	1.39	%
	The Company estimated the relative fair value of the warrants on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		January 24, 2014
	Expected life (year)	5
	Expected volatility	78.39	%
	Expected annual rate of quarterly dividends	0	%
	Risk-free rate(s)	0.37	%
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The Company estimated the relative fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		June 30, 2014
	Expected life (year)		4
	Expected volatility		78.39%- 98.09%
	Expected annual rate of quarterly dividends		0.00%
	Risk-free rate(s)		.37-1.12%

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	12 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table presents the combined activity of stock options issued for the years ended June 30, as follows:
	Stock Options	Number of	Weighted		Weighted	Aggregate
		Shares	Average		Average	Intrinsic
			Exercise Price		Remaining	Value at
			per share ($)		Contractual	Issuance ($)
					Term (years)
	Outstanding at June 30, 2011	535,715		0.35	4.24		439,286
	Granted	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2012	535,715		0.35	3.23		439,286
	Granted	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2013	535,715		0.35	2.23		1,521,429
	Granted	-		-	-		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2014	535,715		0.35	1.23		2,094,643
Stock Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	Stock Warrants
	Stock Warrants	Number of Shares	Weighted		Weighted	Aggregate
			Average		Average	Intrinsic Value
			Exercise Price		Remaining	($)
			per share ($)		Contractual Term
					(years)
	Outstanding at June 30, 2011	3,263,415		4.095	0.95		-
	Granted	68,572		3.71	2.5		-
	Exercised			-	-		-
	Expired			-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2012	3,331,987		4.06	1.69		-
	Granted	68,572		2.17	3.51		-
	Exercised	-		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
	Outstanding at June 30, 2013	3,400,559		4.025	0.86		134,559
	Granted	5,629,152		5.63	4.37		-
	Exercised	142,500		-	-		-
	Expired	-		-	-		-
	Canceled	-		-	-		-
							-
	Outstanding at June 30, 2014	8,887,211		5.01	2.78		2,278,458

Income_Tax_Provision_Tables

Income Tax Provision (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The following is reconciliation of income tax expense (benefit):
		June 30, 2014		June 30, 2013		June 30, 2012
	Net operating loss carry-forwards	$	11,104,134	$	6,845,928	$	4,283,519
	Research and development credit		6,851,851		5,390,274		2,764,875
	Other		2,216,680		1,796,031		1,701,915
	Gross deferred tax assets		20,172,664		14,032,233		8,750,309
	Valuation allowances		-20,172,664		-14,032,233		-8,750,309
	Deferred tax assets, net	$	-	$	-	$	-

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Details Textual) (USD $)	12 Months Ended	96 Months Ended		12 Months Ended
	Jun. 30, 2014	Sep. 12, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Feb. 15, 2010
				ECMM [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
Product Information [Line Items]	'	'	'	'	'	'
Entity Incorporation, State Country Name	'Colorado	'	'	'	'	'
Entity Incorporation, Date Of Incorporation	25-Jul-00	'	'	'	'	'
Business Acquisition, Name of Acquired Entity	'Edot-com.com, Inc.	'	'	'	'	'
Business Acquisition, Date of Acquisition Agreement	12-May-05	'	'	'	'	'
Common Stock Shares Issued Prorata Basis	'	'	'	1,143	'	'
Stock Issued During Period, Shares, New Issues	2,945,428	2,945,428	'	22,857,143	'	'
Common stock, shares issued	54,620,993	'	47,026,173	28,571,429	'	'
Common stock, shares, outstanding	54,620,993	'	47,026,173	28,571,429	'	'
Business Acquisition, Percentage of Voting Interests Acquired	'	'	'	80.00%	'	'
Preferred stock, shares issued	'	'	'	'	'	2,000,000
Preferred stock	'	'	'	'	'	$7,000
Convertible Preferred Stock, Terms of Conversion	'Only in the event of a change of control of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A change of control is defined as an event in which the Companys shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition.	'	'	'	'The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of three and one half shares of common stock for each share of Series A Preferred Stock.	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details )	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Fair Value Assumptions, Weighted Average Volatility Rate	95.00%	92.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Feb. 01, 2013
Accounting Policies [Line Items]	'	'	'
Series B Convertible Debenture	'	$6,000,000	$6,000,000
Derivative Value	5,699,703	3,824,987	'
Mark to Market	1,874,716	-3,752,933	'
Series B Convertible Debenture [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Series B Convertible Debenture	$6,000,000	$6,000,000	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Begining Balance	$3,751,645	$1,078,698	$17,519
Total Gains or Losses (realized/unrealized) Included in Net (Income) Loss	1,948,058	-1,249,335	-172,245
Included in Other Comprehensive Income Purchases, Issuances and Settlements	0	3,922,282	1,233,424
Transfers in and/or out of Level 3	0	0	'
Ending Balance	5,699,703	3,751,645	1,078,698
Derivative Financial Instruments, Liabilities [Member]	'	'	'
Begining Balance	3,751,645	1,078,698	17,519
Total Gains or Losses (realized/unrealized) Included in Net (Income) Loss	1,948,058	-1,249,335	-172,245
Included in Other Comprehensive Income Purchases, Issuances and Settlements	0	3,922,282	1,233,424
Transfers in and/or out of Level 3	0	0	'
Ending Balance	$5,699,703	$3,751,645	$1,078,698

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 3) (USD $)	Jun. 30, 2014	Jan. 15, 2013
Accounting Policies [Line Items]	'	'
Derivative Carrying Value	$5,699,703	'
Derivative liability Fair Value	5,699,703	2,735,310
Series B Convertible Debentures [Member]	'	'
Accounting Policies [Line Items]	'	'
Derivative Carrying Value	5,699,703	'
Derivative liability Fair Value	5,699,703	'
Fair Value, Inputs, Level 3 [Member]	'	'
Accounting Policies [Line Items]	'	'
Derivative liability Fair Value	5,699,703	'
Fair Value, Inputs, Level 3 [Member] | Series B Convertible Debentures [Member]	'	'
Accounting Policies [Line Items]	'	'
Derivative liability Fair Value	$5,699,703	'

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details Textual) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jan. 21, 2014

Jun. 30, 2014

Feb. 06, 2014

Sep. 25, 2013

Sep. 12, 2013

Sep. 09, 2013

Jun. 30, 2013

Feb. 01, 2013

Jan. 15, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Series B Convertible Debentures [Member]

Series B Convertible Debentures [Member]

Series B Convertible Debentures [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Common Stock [Member]

June 15,2006 [Member]

August 22, 2008 [Member]

June 15, 2008 [Member]

June 30, 2009 [Member]

September 30, 2009 [Member]

August 16 2010 [Member]

August 16 2011 [Member]

August 16 2013 [Member]

September 10, 2013 [Member]

September 10, 2013 [Member]

August 15, 2013 [Member]

November 15, 2013 [Member]

January 24, 2014 [Member]

January 24, 2014 [Member]

February 14, 2014 [Member]

May 15, 2014 [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Alternative Financing [Member]

Placement Agents [Member]

Placement Agents [Member]

June 15, 2008 [Member]

August 16 2010 [Member]

August 16 2011 [Member]

June 15, 2008 [Member]

August 16 2010 [Member]

August 16 2011 [Member]

Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

92.00%

'

'

'

95.00%

'

'

'

Derivative liability Currrent

'

$5,699,703

'

'

'

'

'

'

$2,735,310

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Fair Value, Net

'

5,699,703

'

'

'

'

3,824,987

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

1,408,451

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Interest Conversion Converted Instrument Shares Issued

'

1,142,858

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

'

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Expiration Term

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercise Price

$6.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

$3.50

'

$3.50

$3.50

'

'

$5.17

$5.25

$5.25

$5.17

$6.56

$6.05

$6.05

$3.98

$4.11

'

$2.45

$5.15

$2.80

'

$9.38

$6.34

$4.94

Warrants Expiration Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28-Feb-14

28-Feb-14

28-Feb-14

28-Feb-14

28-Feb-14

30-Jun-15

30-Jun-16

30-Jun-17

31-Mar-14

28-Feb-18

15-Aug-17

15-Nov-17

24-Jan-19

24-Jan-19

14-Feb-18

15-May-18

'

'

'

'

'

'

'

'

Share Price

'

'

'

'

'

'

'

'

'

$1.21

$0.91

'

'

'

$4.26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Terms Of Conversion

'

'Only in the event of a change of control of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A change of control is defined as an event in which the Companys shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,175,776

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

3,193,079

2,990,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured Debt

'

'

'

'

'

'

$6,000,000

$6,000,000

'

$6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Debt Default, Description of Violation or Event of Default

'

'

'

'

'

'

'

'

'

'An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;

'

'The company would redeem the debentures projected initially at 0% of the time and increase monthly by 1.0% to a maximum of 20.0% (from alternative financing being available for a Redemption event to occur);

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 4)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,422,926	3,943,413	3,806,271
Employee Stock Option [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,714	535,714	535,714
Total Stock Option [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,714	535,714	535,714
Warrants Issued One [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	520,286	520,286	520,286
Warrants Issued Two [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	466,486	466,486	466,486
Warrants Issued Three [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	211,429	211,429	211,429
Warrants Issued Four [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	561,628	568,771	568,771
Warrants Issued Five [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,437,871	1,437,871	1,437,871
Warrants Issued Six [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	65,714	65,714	65,714
Warrants Issued Seven [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571	'
Warrants Issued Eight [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571	'
Warrants Issued Nine [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,802,928	'	'
Warrants Issued Ten [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	'	'
Warrants Issued Eleven [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,910	'	'
Warrants Issued Twelve [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	'	'
Warrants Issued Thirteen [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,479,935	'	'
Warrants Issued Fourteen [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	76,306	'	'
Warrants Issued Fifteen [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	'	'
Warrants Issued Sixteen [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,148	'	'
Total Warrants [Member]	'	'	'
Accounting Policies [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,887,212	3,407,699	3,270,557

Financial_Condition_Details_Te

Financial Condition (Details Textual) (USD $)

1 Months Ended

12 Months Ended

96 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

31-May-14

Feb. 28, 2014

Feb. 06, 2014

Jan. 21, 2014

Jan. 24, 2014

Nov. 30, 2013

Sep. 25, 2013

Aug. 31, 2013

Mar. 31, 2013

Feb. 28, 2013

Nov. 30, 2012

Aug. 31, 2012

31-May-12

Mar. 31, 2012

Feb. 29, 2012

Nov. 30, 2011

Aug. 31, 2011

Jun. 30, 2014

Sep. 12, 2013

Sep. 09, 2013

Jun. 30, 2013

Feb. 01, 2013

Jun. 30, 2012

Jun. 30, 2011

Feb. 06, 2014

Jan. 21, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Sep. 05, 2014

Jul. 17, 2014

Jun. 30, 2014

Feb. 01, 2013

Nov. 30, 2011

Warrant [Member]

Warrant [Member]

Warrant [Member]

Long-Term Debentures Payable [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Convertible Debenture [Member]

Series B Convertible Preferred Stock [Member]

Director [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Long-Term Debentures Payable [Member]

Director [Member]

Financial Condition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$36,696,892

'

'

$13,923,245

'

$14,274,985

$9,224,023

'

'

'

'

'

'

'

'

'

'

Purchase Price Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

'

'

$0.00

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

$0.00

'

$0.00

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

'

'

'

'

'

'

'

'

'

$5.25

'

'

Proceeds From Issuance Initial Public Offering

'

'

131,750

393,750

20,030,206

'

'

'

'

'

'

'

'

'

'

'

'

10,308,996

10,308,996

'

'

'

'

'

131,750

393,750

185,624

'

'

'

'

'

'

'

Placement Agents and Attorneys Fees

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

618,540

618,540

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued

'

'

'

'

2,479,935

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase And Sale Of Common Stock

'

'

'

'

3,815,285

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercise Price

'

'

'

$6.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,945,428

2,945,428

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants

17,148

17,148

25,000

75,000

'

17,143

35,357

21,000

71,429

17,143

17,143

17,143

17,143

71,429

17,143

17,143

17,143

'

'

'

'

'

'

'

25,000

75,000

'

'

'

'

'

'

'

'

Long-Term Debt, Excluding Current Maturities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

Derivative, Cap Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

'

'

'

'

'

'

'

'

'

$5.25

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,136,655

2,136,655

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.50

$3.50

$3.50

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,478,292.50

'

'

'

'

'

'

'

'

'

'

7,478,292.50

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,071,986

'

3,071,986

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,367,655

'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Accounts Payable Related Parties Off set By Contractual Advances	$709,221	$546,783	'
Net Account Payable to related party	49,455	163,784	'
Research and development	5,131,523	4,292,909	4,265,933
Due to Related Parties	9,000,000	9,000,000	'
Director [Member] | Long-Term Debentures Payable [Member]	'	'	'
Due to Related Parties, Noncurrent	4,000,000	4,000,000	'
Payments to Fund Long-term Loans to Related Parties	0	0	'
Due to Related Parties, Noncurrent	4,000,000	4,000,000	'
Director [Member] | Long-Term Debentures Payable [Member] | Subsequent Event [Member]	'	'	'
Due to Related Parties, Noncurrent	5,000,000	5,000,000	'
Payments to Fund Long-term Loans to Related Parties	0	0	'
Due to Related Parties, Noncurrent	5,000,000	5,000,000	'
Innohaven, LLC [Member]	'	'	'
Due from Related Parties	4,500,000	0	'
TheraCour Pharma, Inc [Member]	'	'	'
Due from Related Parties	528,720	0	'
Net Account Payable to related party	758,676	710,567	'
Research and development	$2,611,754	$1,988,046	'

Related_Party_Transactions_Det1

Related Party Transactions (Details Textual) (USD $)

12 Months Ended

12 Months Ended

Jun. 30, 2014

Feb. 06, 2014

Jan. 21, 2014

Sep. 25, 2013

Sep. 12, 2013

Sep. 09, 2013

Jun. 30, 2013

Feb. 01, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

Long-Term Debentures Payable [Member]

TheraCour Pharma, Inc [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Description of Transaction

'charge its costs (direct and indirect) plus no more than 30% of direct costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lab Supplies and Chemicals Fees

$25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other General and Administrative Expense

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Payment Percentage Of Net Sales

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Security Deposit

1,000,000

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

709,221

Due to Related Parties, Noncurrent

'

'

'

'

'

'

'

'

4,000,000

4,000,000

4,000,000

5,000,000

5,000,000

5,000,000

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

Debt Instrument, Interest Rate Terms

'

'

'

'

'

'

'

'

'The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal.

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

$3.50

'

'

'

'

'

'

Debt Instrument, Term

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

Long-Term Debt, Excluding Current Maturities

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

'

'

Derivative, Cap Interest Rate

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

Common Stock, Par Or Stated Value Per Share

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

$0.00

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

$3.50

'

'

'

$5.25

'

'

'

Concentrations_Details

Concentrations (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Supplier Concentration Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Net Purchases	$3,454,630	$3,024,029
Accounts Payable	882,246	833,699
Supplier Concentration Risk [Member] | TheraCour Pharma, Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Net Purchases	3,140,474	1,988,046
Accounts Payable	758,676	710,567
Supplier Concentration Risk [Member] | Kard Scientific Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Net Purchases	314,156	1,035,983
Accounts Payable	$123,570	$123,132
Net Purchases [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	39.90%	45.90%
Net Purchases [Member] | TheraCour Pharma, Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	36.20%	30.20%
Net Purchases [Member] | Kard Scientific Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	3.60%	15.70%
Accounts Payable [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	77.70%	85.60%
Accounts Payable [Member] | TheraCour Pharma, Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	75.60%	72.97%
Accounts Payable [Member] | Kard Scientific Inc [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration Risk, Percentage	10.90%	12.64%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
GMP Facility	$3,099,780	$397,407
Office Equipment	30,048	30,048
Furniture and Fixtures	1,400	1,400
Lab Equipment	3,605,514	1,076,793
Total Property and Equipment	6,736,742	1,505,648
Less Accumulated Depreciation	-1,239,986	-1,036,752
Property and Equipment, Net	$5,496,756	$468,896

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation	$203,234	$210,877	$210,877

Trademark_and_Patents_Details

Trademark and Patents (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Trademarks And Patents [Line Items]	'	'
Trademarks and Patents	$458,954	$458,954
Less Accumulated Amortization	-50,696	-41,921
Trademarks and Patents, Net	$408,258	$417,033

Trademark_and_Patents_Details_

Trademark and Patents (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Trademarks And Patents [Line Items]	'	'	'
Amortization	$8,775	$8,774	$8,776

Equity_Transactions_Details

Equity Transactions (Details)	1 Months Ended		12 Months Ended
	Jan. 31, 2014	Sep. 30, 2013	Jun. 30, 2014
Class of Stock [Line Items]	'	'	'
Expected life (year)	'5 years	'5 years	'4 years
Expected volatility	78.39%	78.39%	'
Expected annual rate of quarterly dividends	0.00%	0.00%	0.00%
Risk-free rate(s)	0.37%	1.39%	'

Equity_Transactions_Details_1

Equity Transactions (Details 1)	1 Months Ended		12 Months Ended
	Jan. 31, 2014	Sep. 30, 2013	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'5 years	'5 years	'4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	'	'	78.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	'	'	98.09%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	'	'	0.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	'	'	1.12%

Equity_Transactions_Details_Te

Equity Transactions (Details Textual) (USD $)

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

96 Months Ended

1 Months Ended

12 Months Ended

96 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

31-May-14

Feb. 28, 2014

Feb. 06, 2014

Jan. 21, 2014

Jan. 24, 2014

Sep. 09, 2013

Jan. 31, 2014

Dec. 31, 2013

Nov. 30, 2013

Sep. 25, 2013

Sep. 30, 2013

Aug. 31, 2013

Mar. 31, 2013

Feb. 28, 2013

Nov. 30, 2012

Aug. 31, 2012

Jun. 30, 2012

31-May-12

Mar. 31, 2012

Feb. 29, 2012

Nov. 30, 2011

Aug. 31, 2011

Mar. 31, 2011

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Sep. 12, 2013

Sep. 03, 2013

Feb. 01, 2013

Jan. 24, 2014

Jun. 30, 2014

Sep. 12, 2013

Jan. 24, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Sep. 30, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2013

Sep. 30, 2013

Oct. 31, 2013

Mar. 31, 2013

Jun. 30, 2012

Mar. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Feb. 28, 2013

Nov. 30, 2011

Jun. 30, 2014

Jun. 30, 2013

Nov. 30, 2011

Jun. 30, 2012

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2012

Warrant [Member]

Warrant [Member]

Warrant [Member]

Common Stock [Member]

Common Stock [Member]

Preferred Series A shares [Member]

Preferred Series A shares [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Consulting Services [Member]

Consulting Services [Member]

Consulting Services [Member]

Consulting Services [Member]

Subsequent Event [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Director [Member]

Initial Closing [Member]

Initial Closing [Member]

Subsequent Closing [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase and Sale Of Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

142,857

'

'

'

1,429

'

'

'

'

'

Preferred stock, par value (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

$0.00

$0.00

$0.00

'

$0.00

$0.00

$0.00

$0.00

'

'

Purchase Price Per Share

'

'

'

'

'

$3.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$35

'

'

'

$3,500

'

'

'

'

'

Purchase Of Initial Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

71,429

'

'

71,429

'

'

'

'

714

714

Purchase Price Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,500,000

'

'

$2,500,000

'

'

'

'

$2,500,000

$2,500,000

Proceeds from Issuance Initial Public Offering

'

'

131,750

393,750

20,030,206

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,308,996

'

10,308,996

'

'

'

'

185,624

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement Agents and Attorneys Fees

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

618,540

'

618,540

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Midtown Cash Fee Percentage

'

'

'

'

1200000.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued to a Director for services rendered (in shares)

'

'

'

'

'

'

'

4,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

71,429

'

'

'

'

'

'

'

'

'

'

1,348

177,359

'

5,501

3,178

2,247

5,940

42,979

'

10,311

10,304

4,988

8,520

'

'

'

300,000

'

'

'

'

'

2,858

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued For Services

'

'

'

'

'

'

'

21,000

'

'

'

'

'

31,800

34,200

40,800

'

47,400

181,874

51,000

56,400

56,400

'

297,860

'

'

2,500

'

'

'

'

'

'

'

2

1,894,975

'

11,250

11,250

11,250

'

84,960

'

21,000

39,000

21,000

18,750

'

'

'

345,172

634,407

'

'

'

'

3,287

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity, Reverse Stock Split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 for 3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

'

'

$0.00

$0.00

'

$0.00

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

$0.00

$0.00

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

Stock Issued During Period Price Per Share One

'

'

'

$5.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) the daily volume weighted average of actual trading prices of the Common Stock on the trading market (the VWAP) for the ten consecutive trading days immediately prior to a conversion date multiplied by 0.85 and (ii) the VWAP for the trading day immediately prior to a conversion date multiplied by 0.88. In the event that the conversion price does not equal or exceed $0.70 (the Floor),

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number Of Common Stock To Be Issued Upon Conversion Of Warrants

17,148

17,148

25,000

75,000

'

'

'

'

17,143

35,357

'

21,000

71,429

17,143

17,143

17,143

'

17,143

71,429

17,143

17,143

17,143

'

'

'

'

'

'

'

'

2,479,935

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

169,643

'

169,643

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Price Per Share

$3.16

$3.32

'

'

'

$5.25

'

'

$6.56

'

$5.25

$5.17

$0.00

$1.86

$2.00

$2.38

$0.00

$2.77

$0.00

$3.82

$3.32

$4.93

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

Fair Value Of Common Stock Warrant Issued During Period For Consulting Services

31,895

30,352

'

'

'

113,696

'

'

31,552

'

113,696

106,050

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercise Period

'

'February, 2018

'

'

'

'

'

'

'November, 2017

'

'September, 2018

'August, 2017

'

'February 2017

'November 2016

'August 2016

'

'May, 2016

'

'February, 2016

'November, 2015

'February, 2015

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock and Warrants Issued During Period Private Placement Value Issues Eighteen

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

Stock Issued During Period Price Per Share Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued During Period Settlement Of Accounts Payable Shares

'

'

'

'

'

'

'

7,143

'

'

58,910

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,624

'

'

'

'

'

5,025

'

'

'

20,695

'

'

'

'

571,429

'

'

'

'

'

'

'

'

'

'

Common Stock Issued During Period Settlement Of Accounts Payable Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

72,000

'

'

'

'

'

35,995

445,044

'

'

192,041

60,000

'

'

'

665,497

'

'

'

'

'

'

'

'

'

'

Series Preferred Shares Issued During Period Value Issue One

'

'

'

'

'

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series B Preferred Shares Issued During Period Value Issue One

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

Series B Preferred Shares Issued During Period Value Issue Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued During Period Convestion Of Series B Preferred Shares Issue Seventeen

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,429

'

'

'

'

'

'

'

'

'

Conversion Price Per Share For Initial Closing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.14

'

'

'

'

'

Conversion Price Per Share For Subsequent Closing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Authorized After Stock Split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85,714,286

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,714,286

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

4,000,000

'

'

'

10,000,000

10,000,000

'

'

'

10,000,000

10,000,000

'

'

Common Stock Shares Outstanding After Stock Split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,028,701

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,990,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,193,079

2,990,000

'

'

'

0

0

'

'

'

0

0

'

'

Warrants Exercise Price

'

'

'

$6.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,945,428

'

2,945,428

'

'

'

'

'

3,815,285

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description Of Offering

'

'

'

'

'

'the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share

'the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

'

'

'

113,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Adjustment of Warrants

'

'

'

'

7,762,196

5,684,380

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price Per Unit Description

'

'

'

'The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Companys stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Companys stock onFriday, January 17, 2014. Each Unit consisted of one share of the Companys common stock, par value $0.001 per share (the Common Stock) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (Warrant),

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note, Stock Split, Conversion Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Estimated Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$199,849

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Shares Conversion Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Measurements, Significant Assumptions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'a. The common stock price (post-reverse split) was in the range $2.45 to $3.90; b. 47,026,173 to 54,614,930 shares outstanding and Series A Preferred shares with 2,572 (postsplit 9/10/13) issued monthly ; and 169,644 issued annually to employees . c. A 5.36% premium over the common shares for the voting preferences; d. 54,506,459 to 62,208,499 total voting shares and the monthly shares representing voting rights of 0.042% to 0.484% of the total; and the annual shares representing 1.02% to 2.389% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 anda restricted term of 3.67 to 2.67 years; f. 42.87% to 27.11% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 121.97% to 265.70% volatility, 0.37% to 1.62% riskfree rate) applied to the converted common.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted Average Exercise Price per share , Outstanding	$0.10	'	'	'
Equity Option [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of Shares, Granted	0	0	0	'
Number of Shares, Exercised	0	0	0	'
Number of Shares, Expired	0	0	0	'
Number of Shares, Canceled	0	0	0	'
Number of Shares, Outstanding	535,715	535,715	535,715	535,715
Weighted Average Exercise Price per share, Granted	$0	$0	$0	'
Weighted Average Exercise Price per share, Exercised	$0	$0	$0	'
Weighted Average Exercise Price per share, Expired	$0	$0	$0	'
Weighted Average Exercise Price per share, Canceled	$0	$0	$0	'
Weighted Average Exercise Price per share , Outstanding	$0.35	$0.35	$0.35	$0.35
Weighted Average Remaining Contractual Term, (year) Granted	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Exercised	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Expired	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Canceled	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Outstanding	'1 year 2 months 23 days	'2 years 2 months 23 days	'3 years 2 months 23 days	'4 years 2 months 26 days
Aggregate Intrinsic Value, Granted	$0	$0	$0	'
Aggregate Intrinsic Value, Exercised	0	0	0	'
Aggregate Intrinsic Value, Expired	0	0	0	'
Aggregate Intrinsic Value, Canceled	0	0	0	'
Aggregate Intrinsic Value, Outstanding	$2,094,643	$1,521,429	$439,286	$439,286

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted Average Exercise Price per share , Outstanding	$0.10	'	'	'
Stock Warrants [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of Shares, Granted	5,629,152	68,572	68,572	'
Number of Shares, Exercised	142,500	0	'	'
Number of Shares, Expired	0	0	'	'
Number of Shares, Canceled	0	0	0	'
Number of Shares, Outstanding	8,887,211	3,400,559	3,331,987	3,263,415
Weighted Average Exercise Price per share, Granted	$5.63	$2.17	$3.71	'
Weighted Average Exercise Price per share, Exercised	$0	$0	$0	'
Weighted Average Exercise Price per share, Expired	$0	$0	$0	'
Weighted Average Exercise Price per share, Canceled	$0	$0	$0	'
Weighted Average Exercise Price per share , Outstanding	$5.01	$4.03	$4.06	$4.09
Weighted Average Remaining Contractual Term, (year) Granted	'4 years 4 months 13 days	'3 years 6 months 4 days	'2 years 6 months	'
Weighted Average Remaining Contractual Term, (year) Exercised	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Expired	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Canceled	'0 years	'0 years	'0 years	'
Weighted Average Remaining Contractual Term, (year) Outstanding	'2 years 9 months 11 days	'10 months 10 days	'1 year 8 months 8 days	'11 months 12 days
Aggregate Intrinsic Value, Granted	$0	$0	$0	'
Aggregate Intrinsic Value, Exercised	0	0	0	'
Aggregate Intrinsic Value, Expired	0	0	0	'
Aggregate Intrinsic Value, Canceled	0	0	0	'
Aggregate Intrinsic Value, Outstanding	$2,278,458	$134,559	$0	$0

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details Textual)	12 Months Ended
	Jun. 30, 2014
June 30, 2015 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Exercisable	3,263,414
Warrants Expiration Date	30-Jun-15
June 30, 2016 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Exercisable	68,572
Warrants Expiration Date	30-Jun-16
June 30, 2017 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Exercisable	68,571
Warrants Expiration Date	30-Jun-17
June 30, 2019 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Exercisable	5,359,169
Warrants Expiration Date	30-Jun-19
June 30 2018 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Exercisable	127,487
Warrants Expiration Date	30-Jun-18

Income_Tax_Provision_Details

Income Tax Provision (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Provision [Line Items]	'	'	'
Net operating loss carry-forwards	$11,104,134	$6,845,928	$4,283,519
Research and development credit	6,851,851	5,390,274	2,764,875
Other	2,216,680	1,796,031	1,701,915
Gross deferred tax assets	20,172,664	14,032,233	8,750,309
Valuation allowances	-20,172,664	-14,032,233	-8,750,309
Deferred tax assets, net	$0	$0	$0

Income_Tax_Provision_Details_T

Income Tax Provision (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Provision [Line Items]	'	'	'
Operating Loss Carryforwards, Expiration Date	30-Jun-34	'	'
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves	$33,238,766	'	'
Deferred Tax Assets Valuation Allowance Increase	$6,140,431	$5,281,924	$2,206,785

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

Feb. 28, 2011

Mar. 31, 2010

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2010

Mar. 31, 2010

30-May-13

30-May-13

sqft

Series A Convertible Preferred Stock [Member]

Chief Executive Officer [Member]

Chief Scientific Officer [Member]

President [Member]

President [Member]

Vice President [Member]

Vice President [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Maximum [Member]

Maximum [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Commitments and Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Space For Office and Laboratory

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Monthly Base Rent

$8,695

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease Expiration Date

28-Feb-11

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense, Net

'

'

104,340

102,030

110,633

'

'

'

'

'

'

'

'

'

Minimum Annual Base Salary

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Financing

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Employment Agreement Term

'

'4 years

'

'

'

'

'

'0 years

'

'

'0 years

'

'

'

Common stock, shares issued

'

'

54,620,993

47,026,173

'

'

'

35,715

'

'

35,715

'

'

'

Additional Common Stock Shares Issued

'

'

'

'

'

'

'

35,715

'

'

35,715

'

'

'

Preferred stock, shares issued

'

'

'

'

'

71,429

'

'

'

'

'

26,786

'

2,572

Additional Preferred Stock Shares Issued

'

'

'

'

'

71,429

'

'

'

'

'

26,786

'

'

Increase In Base Salary

'

'

'

'

'

'

$300,000

$150,000

$275,000

$300,000

$150,000

'

$9,000

'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

12 Months Ended

12 Months Ended

Jun. 30, 2014

Feb. 06, 2014

Jan. 21, 2014

Sep. 25, 2013

Sep. 12, 2013

Sep. 09, 2013

Jun. 30, 2013

Feb. 01, 2013

Jun. 30, 2014

Jun. 30, 2014

Sep. 05, 2014

Jul. 17, 2014

Jun. 30, 2014

Long-Term Debentures Payable [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Director [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Registered Warrants [Member]

Long-Term Debentures Payable [Member]

Director [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

'

$0.00

Long-Term Debt, Excluding Current Maturities

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

Derivative, Cap Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

$3.50

'

'

'

'

$5.25

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

2,136,655

2,136,655

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

$3.50

$3.50

$3.50

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

'

'

'

'

3,071,986

'

3,071,986

'

Proceeds from Warrant Exercises

$7,478,292.50

'

'

'

'

'

'

'

'

$7,478,292.50

'

'

'

Derivative, Description of Terms

'The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the “Redemption Payment”) in cash or, at the option of the Holder, a number of shares of the Company’s Common Stock. If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the “Redemption Date”), the Company must redeem the Debenture by delivering to the Holder 951,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, and additional interest of 7% per annum for the period from the Closing Date to the Redemption Date.As additional interest on the Debenture, the Company shall issue 187,000 shares of its restricted Series A Preferred Stock (the “Series A”) to the Holder. Each shares of Series A votes at 9 votes per share. In addition, only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects.

'

'

'

'

'

'

'

'

'

'

'

'